<?xml version="1.0" encoding="UTF-8"?>
<unload unload_date="2018-10-01 21:37:43">
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>c81f79cedb18ab00b86770c08c9619a8</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012624 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012624</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Mechanism of cetuximab resistance in colorectal cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012624">cd7ff502db58ab00b86770c08c961955</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:16:33</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>c81f79cedb18ab00b86770c08c9619a8</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">3e7f7d02db58ab00b86770c08c961965</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Colon/colorectal</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The investigators found that colorectal cancer cells growing in vitro in the presence of collagen exhibit either a cystic colony morphology or spiky colony morphology.&nbsp; The anti-EGFR antibody cetuximab inhibited growth of the cystic type of colonies but the spiky colonies were resistant.&nbsp; Spiky colony resistance was associated with tyrosine phosphorylation of Met and Ron as well as upregulation of VCAN.&nbsp; VCAN expression strongly correlated with reduced survival and could potentially be used as a prognostic marker.&nbsp; In a separate study they showed that another form of colorectal cancer acquired resistance to cetuximab involving an epigenetic cause that has therapeutic implications.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>These studies were led by investigators associated with the Vanderbilt Univ. GI SPORE and involved collaborations with several institutions including State Key Laboratory of Cancer Biology (Xi'an, China), Jiaen Genetics Laboratory (Xiamen, China), Gibbs Cancer Center and Research Institute (Spartanburg, SC), Pediatric Hematology and Oncology (Hannover, Germany), Whitehead Institute for Biomedical Research (Cambridge, MA), Dept. of Human Genetics (Emory Univ., Atlanta, GA).</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMIDs: 28320945 and 29035371</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>d226b54adb18ab00b86770c08c96192a</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012591 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012591</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>NCI Pediatric Provocative Question (Pediatric PQ) Program</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012591">1676710adb18ab00b86770c08c961983</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:37:19</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>d226b54adb18ab00b86770c08c96192a</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">ff76b94adb18ab00b86770c08c961986</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Pediatric, Rare</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>The Pediatric PQ Program aims to challenge the scientific community to develop innovative approaches to address challenging and understudied problems in childhood cancer research. The Program has assembled 9 important questions in pediatric cancer and includes FOAs for R01 and R21 applications. In FY2017, the Pediatric PQ Program supported 5 R01 and 2 R21 awards. These projects range from investigating mechanisms of rhabdomyosarcoma and AML oncogenesis, to developing predictive models for long-term adverse effects of therapy, to developing new model systems to study premature aging in pediatric cancer patients.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CSSI</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-018.html</a></div>
<div><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-017.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-017.html</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>d8c9821adb14eb00b86770c08c9619cb</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012688 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012688</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Low immunosuppressive burden after HLA-matched related or unrelated BMT using post-transplantation cyclophosphamide</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012688">f7f9861adb14eb00b86770c08c9619b8</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:41:05</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>d8c9821adb14eb00b86770c08c9619cb</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">410a4a1adb14eb00b86770c08c9619d3</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Patients who undergo allogeneic stem cell transplantation (alloBMT) are at substantial risk for developing life-threatening complications from graft-vs-host disease, and generally undergo intensive and prolonged immunosuppressive therapy to prevent or treat this condition.&nbsp; However, cyclophosphosphamide in the early post-transplant period (PTCy) has been shown to reduce GVHD as a single agent prophylaxis after bone marrow grafting, but whether a requirement for immunosuppressive supplemental treatment for patients developing GVHD after cyclophosphamide treatment was not known. This retrospective study suggested that the PTCy minimizes the global immunosuppressive burden by patients undergoing HLA-matched alloBMT.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28049637</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Post-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>04f58a16db14eb00b86770c08c961909</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012677 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012677</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>SBIR Funded Technologies took part in over 90 clinical trials in 2017</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012677">a8364656db14eb00b86770c08c961920</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:24:29</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>04f58a16db14eb00b86770c08c961909</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">2d360e56db14eb00b86770c08c96197b</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Brain</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>SBIR-Funded technologies were included in over 90 clinical trials in 2017.&nbsp; A wide range of SBIR-funded technology types were included in trials.&nbsp; Tocagen's Toca 511 retroviral replicating vector is currently involved in five separate clinical trials, Epic Sciences' cancer stem cell (CTC) evaluation tools are involved in 60 clinical trials, and Bexion Pharmaceuticals recently initiated a phase Ib clinical study after receiving an orphan drug designation from the FDA for saposin, the active ingredient in their lead therapeutic, BXQ-350.&nbsp; The Orphan drug designation was granted to Bexion for treatment of glioblastoma multiforme.&nbsp; Additionally, Oncoceutics expanded their phase 2 clinical trial of SBIR-funded small molecule therapeutic, ONC-201.&nbsp; The expanded trial now allows single-patient compassionate use of ONC-201 for glioma patients with a missense histone H3 mutation.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>SBIR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="http://www.epicsciences.com/biopharma-solutions/clinical-trials/">http://www.epicsciences.com/biopharma-solutions/clinical-trials/</a></div>
<div><a href="https://clinicaltrials.gov/ct2/show/NCT03134131?term=ONcoceutics&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03134131?term=ONcoceutics&amp;rank=1</a></div>
<div><a href="https://clinicaltrials.gov/ct2/show/NCT02859857?term=Bexion&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02859857?term=Bexion&amp;rank=1</a></div>
<div><a href="https://clinicaltrials.gov/ct2/results?cond=&amp;term=Tocagen&amp;cntry1=&amp;state1=&amp;recrs=">https://clinicaltrials.gov/ct2/results?cond=&amp;term=Tocagen&amp;cntry1=&amp;state1=&amp;recrs=</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>49c3b9c6db18ab00b86770c08c961930</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012586 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012586</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Uncovered cause of genetic anomaly linked to cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012586">bc04f182db18ab00b86770c08c96190e</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:26:33</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>49c3b9c6db18ab00b86770c08c961930</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">ca043dc6db18ab00b86770c08c9619f2</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>A genetic anomaly called uniparental disomy (UPD) is associated with many diseases, including cancer, but scientists have not been able to identify what causes UPD. Now, CCR investigator Shiv Grewal has identified a specific genetic process that contributes to this abnormality.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28199302</div>
<div><a href="https://ccr.cancer.gov/news/article/researchers-uncover-cause-of-genetic-anomaly-linked-to-cancer">https://ccr.cancer.gov/news/article/researchers-uncover-cause-of-genetic-anomaly-linked-to-cancer</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>e8e1cac6db18ab0054d8ff621f9619e2</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012640 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012640</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Study estimates number of US women living with metastatic breast cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012640">7432cec6db18ab0054d8ff621f9619b2</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:28:33</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>e8e1cac6db18ab0054d8ff621f9619e2</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">25320a0adb18ab0054d8ff621f9619b2</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Breast, Metastatic</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>In May, DCCPS authors published a study showing that the number of women in the US living with distant metastatic breast cancer (MBC), the most severe form of the disease, is growing -- likely due to the aging of the population and improvements in treatment. The researchers came to this finding by estimating the number of US women living with MBC, or breast cancer that has spread to distant sites in the body, including women who were initially diagnosed with metastatic disease, and those who developed MBC after an initial diagnosis at an earlier stage.&nbsp; The researchers also found that median and five-year relative survival for women initially diagnosed with MBC is improving, especially among younger women.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCCPS</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=%22Cancer+epidemiology%2C+biomarkers+%26+prevention+%3A+a+publication+of+the+American+Association+for+Cancer+Research%2C+cosponsored+by+the+American+Society+of+Preventive+Oncology%22%5BJour%5D+AND+2017%5Bpdat%5D+AND+Mariotto+A%5Bauthor%5D&amp;cmd=detailssearch">https://www.ncbi.nlm.nih.gov/pubmed?term=%22Cancer+epidemiology%2C+biomarkers+%26+prevention+%3A+a+publication+of+the+American+Association+for+Cancer+Research%2C+cosponsored+by+the+American+Society+of+Preventive+Oncology%22%5BJour%5D+AND+2017%5Bpdat%5D+AND+Mariotto+A%5Bauthor%5D&amp;cmd=detailssearch</a></div>
<div>NCI press release: <a href="https://www.cancer.gov/news-events/press-releases/2017/metastatic-breast-cancer-survival-rates">https://www.cancer.gov/news-events/press-releases/2017/metastatic-breast-cancer-survival-rates</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Population Science</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>15bc3dc2db18ab0054d8ff621f9619d9</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012612 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012612</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Low-cost, high coverage single-cell sequencing technologies</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012612">e51db506db18ab0054d8ff621f9619f0</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:06:13</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>15bc3dc2db18ab0054d8ff621f9619d9</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">6e1df506db18ab0054d8ff621f961937</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Research funded by the Cancer Systems Biology Consortium resulted in development of low-cost and easily accessible methods for single-cell RNA sequencing. The two methods, Seq-Well from MIT and Plate-seq from Columbia University, provide community accessible methods for single-cell analysis utilizing droplet-based sequencing (MIT) or plate-based sequencing (Columbia) and decrease the cost of high-coverage transcriptomics to less than $20 total per sample. These substantial cost savings and ease-of-use technical improvements will facilitate a deeper understanding of the tumor ecosystem and how it changes in response to treatment.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMIDs 28740083; 28192419&nbsp;</div>
<div>Press releases: (Plate Seq) <a href="https://www.genomeweb.com/sequencing/plate-seq-method-adds-expression-regulatory-insights-cell-screens">https://www.genomeweb.com/sequencing/plate-seq-method-adds-expression-regulatory-insights-cell-screens</a></div>
<div>(Seq-Well) <a href="http://news.mit.edu/2017/making-single-cell-rna-sequencing-widely-available-0213">http://news.mit.edu/2017/making-single-cell-rna-sequencing-widely-available-0213</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>5777f902db18ab0054d8ff621f96197d</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012595 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012595</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>NCI Cancer Research Data Commons</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012595">e1283d02db18ab0054d8ff621f96199f</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:44:38</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>5777f902db18ab0054d8ff621f96197d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">79897182db18ab0054d8ff621f961990</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Building upon the experience gained from the GDC and the CGC Pilots, the NCI is creating a foundational data science infrastructure to connect repositories, analytical tools, and knowledge bases, allowing researchers across the cancer community to find, analyze, share, and visualize many types of data, share tools and methods, and leverage the elastic compute of the cloud. This infrastructure will allow for integrated access to new data types in addition to genomics, such as imaging, and proteomic data. The effort also includes development of an expandable framework that defines the core principles of a data commons and provide reusable components, such as workspaces, secure authentication and authorization, domain-specific data models and dictionaries, all of which can be leveraged to quickly stand up new commons and incorporate new data types. Open and integrated data access and tools will support the PMI and Cancer Moonshot goals of expediting discovery of new cancer treatments and improving outcomes for patients.</div>
<div>&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CBIIT</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<div>NCI CBIIT (Tanja Davidsen, Allen Dearry); Leidos (John Otridge)</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://cbiit.cancer.gov/ncip/cancer-data-commons">https://cbiit.cancer.gov/ncip/cancer-data-commons</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>a6b0ce86db18ab0054d8ff621f96190c</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012633 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012633</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Screen to Save: A National Outreach Campaign to Promote Colorectal Cancer (CRC) Awareness and Screening in Medically Underserved Communities</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012633">8b118e86db18ab0054d8ff621f961990</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:23:47</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>a6b0ce86db18ab0054d8ff621f96190c</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">77110ac6db18ab0054d8ff621f9619e5</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Colon/colorectal</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>CRCHD launched the Screen to Save national initiative in March of 2017 to promote CRC awareness and screening among medically underserved populations including racial/ethnic minorities and rural populations. Leveraging existing programs - National Outreach Network (NON), Geographical Management of Cancer Health Disparities Program (GMaP), and Programs to Advance Cancer Health Equities (PACHE) - the campaign was initiated in nearly 40 geographically diverse locations throughout the United States, including Puerto Rico and Guam. To date, more than 4,000 pre- and post-educational activity surveys have been collected and are currently being analyzed. They contain demographic information, knowledge of CRC risk factors and screening, screening histories, family histories of CRC, and intentions to screen. A subset of the sites is collecting 3-month follow-up information regarding subsequent CRC screenings among participants and existing linkages to health care to inform best practices regarding not only CRC screening and follow-up in medically underserved communities, but also serve as a model for educational outreach and screening/follow-up for all screenable cancers. Two Screen to Save NCI Facebook Live events were held in March for Colorectal Cancer Awareness Month, one in English and the other was the first ever NCI Spanish-language Facebook Live (see URL links below). Three Twitterchats were co-hosted by CRCHD in the month of March, as well.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CRCHD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI designated-Cancer Centers with a NON-funded Community Health Educator</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://www.youtube.com/watch?v=COgYKnV96Dk">https://www.youtube.com/watch?v=COgYKnV96Dk</a> ; <a href="https://www.youtube.com/watch?v=Ta4Bksygrn8">https://www.youtube.com/watch?v=Ta4Bksygrn8</a> ; Huffington Post blog by Dr. Springfield and Dr. Martinez: We're Doing Something About Colorectal Cancer Disparities, <a href="https://www.huffingtonpost.com/entry/were-doing-something-about-colorectal-cancer-disparities_us_59249ab0e4b09c5b6bf92c97">https://www.huffingtonpost.com/entry/were-doing-something-about-colorectal-cancer-disparities_us_59249ab0e4b09c5b6bf92c97</a> ; and, Several press releases by NCI-funded CHE sites were also published</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Population Science</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>f64e79cedb18ab00b86770c08c9619a1</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012620 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012620</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012620">c09e358edb18ab00b86770c08c9619ba</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:12:39</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>f64e79cedb18ab00b86770c08c9619a1</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">1d9e7102db58ab00b86770c08c9619d0</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Thyroid</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>This study determined that a small increase in ERK inhibition markedly increased the expression of thyroid differentiation genes, increased iodide accumulation in cancer cells, and thereby improved responses to Radioiodide (RAI) therapy. These data suggest that potent inhibition of ERK signaling is required to adequately induce iodide uptake and indicate that this is a promising strategy for the treatment of BRAF-mutant thyroid cancer.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Involved NCI SPORE P50-CA72012 investigators, including Drs. James Fagin and Alan Ho</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 27669459</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>2b7f7dcedb18ab00b86770c08c9619fa</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012626 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012626</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Targeting glutamine metabolism and transport in colorectal cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012626">d0df7d02db58ab00b86770c08c961982</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:18:08</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>2b7f7dcedb18ab00b86770c08c9619fa</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">71dfb142db58ab00b86770c08c96191a</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Colon/colorectal</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Recent studies from two gastrointestinal (GI) cancer SPOREs have recently led to a better understanding of the mechanism by which cancer cells (colorectal cancer cells in particular) leverage glutamine as an energy source to replenish the TCA cycle and generate ATP.&nbsp; Investigators from the Case GI SPORE show that oncogenic PIK3CA mutations reprograms metabolism in colorectal cancer cells so that they are more dependent on glutamine and suggest that targeting glutamine metabolism may be an effective therapy.&nbsp; Investigators from the Vanderbilt SPORE have developed a new drug, V-9302, that targets the glutamine transporter ASCT2 and blocks transmembrane glutamine flux.&nbsp; They go on to show that this agent arrests tumor growth in multiple mouse models of colorectal cancer.&nbsp;&nbsp;</div>
<p>&nbsp;</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<div>The first study was a collaboration between the Case Western Reserve GI SPORE led by Sanford Markowitz, MD, PhD and investigators from The Cancer Center at Johns Hopkins University.&nbsp; The collaboration was led by investigators at Case Western Reserve University.&nbsp; The second study arose from research performed in the Vanderbilt University GI SPORE headed by Robert Coffey, MD</div>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 27321283.&nbsp; Note that the Vanderbilt study is in press and does not have a PMID yet: Schulte et al. (2017) Nature Medicine, in press.</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>79fef946db18ab0054d8ff621f96197c</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012623 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012623</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Project ECHO Launch in National Cancer Control Planning and Cervical Cancer ScreeningÂ </short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012623">e84fbd46db18ab0054d8ff621f961972</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:15:42</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>79fef946db18ab0054d8ff621f96197c</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">5d4fbd46db18ab0054d8ff621f9619a2</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Cervical</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Project ECHO is a collaborative medical education model that aims to build workforce and knowledge capacity, through use of online videoconferencing to allow for knowledge exchange across interdisciplinary teams on relevant medical, healthcare, and health systems related topics.&nbsp; The CGH Project Echo Cancer Control Planning Program will link participants active in cancer control planning in low- and middle-income country settings with researchers, regional colleagues, and relevant technical experts, through monthly ECHO sessions that will provide virtual didactic instruction, case study learning, and knowledge exchange on relevant evidence-based cancer control planning principles.&nbsp; These sessions will relay evidence-based, general cancer control principals and related to cervical cancer screening. The CGH Project ECHO program&rsquo;s primary goals are to increase participant knowledge of the aforementioned topics, improve the application of knowledge, including evidence-based practices and policies, and to increase collaboration among participants and experts who are active in cancer control planning in the participating countries.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CGH</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references/>
<x_26385_crs_kd_u_kb_research_type>Cancer Control</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>95aa821adb14eb00b86770c08c9619a6</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012690 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012690</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012690">c5fa4a1adb14eb00b86770c08c96199a</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:45:16</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>95aa821adb14eb00b86770c08c9619a6</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">2afac25adb14eb00b86770c08c9619ee</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Melanoma</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>A revised manual by the American Joint Committee on Cancer (AJCC) for staging melanoma was issued based on an international database housed at MD Anderson and headed by members of the SPORE biospecimen core. Samples were collected worldwide since 1998 of melanoma tumors at Stages I-III from over 49,000 patients. The revised staging includes updated nomenclature and several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. This evidence-based revision of the AJCC melanoma staging system will guide prognosis, planning treatments, and stratifying patients for clinical trials. Also, it supports a centralized cancer registry for the design, conduct, and analysis of clinical trials.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>The University of Texas MD Anderson Cancer Center SPORE in Melanoma; Pathology Core</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 29028110</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Post-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>e1604e86db18ab0054d8ff621f961926</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012630 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012630</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>NCI SBIR-Funded test becomes first genomics-based lung cancer screen to receive CMS coverage</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012630">80a0ce86db18ab0054d8ff621f96190a</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:21:40</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>e1604e86db18ab0054d8ff621f961926</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">20a0c2c6db18ab0054d8ff621f961943</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Lung</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Veractye released a series of announcements in 2017 demonstrating significant commercialization milestones for its Percepta Bronchial Genomic Classifier.&nbsp; The Percepta genomic test identifies patients with lung nodules who are at a low-risk of developing cancer, therefore reducing the need for invasive testing.&nbsp; Patients with lung nodules who are at low-risk of developing cancer do not undergo treatment, but are monitored by their doctor and sometimes highly-invasive medical procedures are needed to identify them as low-risk.&nbsp; A Veracyte-sponsored study of just under 400 patients showed that 50% fewer patients needed to undergo invasive testing for lung cancer because the Percepta test identified them as low-risk of developing cancer.&nbsp; In 2017, Percepta was the first genomic test to gain Medicare coverage for lung cancer screening and diagnosis.&nbsp; In 2017, more than 220,000 new cases of lung cancer were reported in the United States according the NCI SEER data.&nbsp; The NCI SBIR Program funded some of the initial work on Percepta(R) under a previous name, Bronchogen.&nbsp; Allegro Diagnostics, the originators of the Bronchogen test and recipients of NCI SBIR funding from 2009-2011 was acquired by Veracyte in 2014.&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>SBIR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="http://investor.veracyte.com/releasedetail.cfm?releaseid=1010503">http://investor.veracyte.com/releasedetail.cfm?releaseid=1010503</a>&nbsp; <a href="http://investor.veracyte.com/releasedetail.cfm?ReleaseID=1047124">http://investor.veracyte.com/releasedetail.cfm?ReleaseID=1047124</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Cancer Control</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>a0804252db14eb00b86770c08c96194d</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012664 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012664</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CECÂ·3): a multicenter, randomized, controlled, phase 3 trial</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012664">37e04e12db14eb00b86770c08c9619a4</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:01:30</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>a0804252db14eb00b86770c08c96194d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">b8f04a52db14eb00b86770c08c9619de</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Brain, Metastatic</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The study showed that stereotactic radiosurgery preserved cognitive function better compared to whole brain radiation therapy and should be considered a standard of care.&nbsp; Between Nov 10, 2011, and Nov 16, 2015, 194 patients were enrolled and randomly assigned to SRS (98 patients) or WBRT (96 patients). Median follow-up was 11&middot;1 months (IQR 5&middot;1-18&middot;0). Cognitive-deterioration-free survival was longer in patients assigned to SRS (median 3&middot;7 months [95% CI 3&middot;45-5&middot;06], 93 events) than in patients assigned to WBRT (median 3&middot;0 months [2&middot;86-3&middot;25], 93 events; hazard ratio [HR] 0&middot;47 [95% CI 0&middot;35-0&middot;63]; p&amp;lt;0&middot;0001), and cognitive deterioration at 6 months was less frequent in patients who received SRS than those who received WBRT (28 [52%] of 54 evaluable patients assigned to SRS vs 41 [85%] of 48 evaluable patients assigned to WBRT; difference -33&middot;6% [95% CI -45&middot;3 to -21&middot;8], p&amp;lt;0&middot;00031). Median overall survival was 12&middot;2 months (95% CI 9&middot;7-16&middot;0, 69 deaths) for SRS and 11&middot;6 months (9&middot;9-18&middot;0, 67 deaths) for WBRT (HR 1&middot;07 [95% CI 0&middot;76-1&middot;50]; p=0&middot;70). The most common grade 3 or 4 adverse events reported with a relative frequency greater than 4% were hearing impairment (three [3%] of 93 patients in the SRS group vs eight [9%] of 92 patients in the WBRT group) and cognitive disturbance (three [3%] vs five [5%]). There were no treatment-related deaths.&nbsp; Decline in cognitive function was more frequent with WBRT than with SRS and there was no difference in overall survival between the treatment groups. After resection of a brain metastasis, SRS radiosurgery should be considered one of the standards of care as a less toxic alternative to WBRT for this patient population.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28687377</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>f0814ec6db18ab0054d8ff621f96196e</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012637 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012637</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>NCI and partners publish key findings on cancer trends in the US including cancer survivorship trends</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012637">b4d18ec6db18ab0054d8ff621f961994</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:26:55</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>f0814ec6db18ab0054d8ff621f96196e</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">6dd1060adb18ab0054d8ff621f961977</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>The Annual Report to the Nation on the Status of Cancer reported on cancer trends in the US and included a special section focused on cancer survivorship. The researchers reported that overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups.&nbsp; Several, but not all cancer types, showed a significant improvement over time for both early- and late-stage disease, and varied significantly by race/ethnicity and state.&nbsp; Five-year survival for cancers diagnosed in 2006-2012 increased significantly for all but two types of cancer: cervix and uterus.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCCPS</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>The report is jointly issued by the Centers for Disease Control and Prevention (CDC), the North American Association of Central Cancer Registries</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://seer.cancer.gov/report_to_nation/">https://seer.cancer.gov/report_to_nation/</a></div>
<div><a href="https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djx030">https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djx030</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Population Science</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>aadfbd5edbd0eb00b86770c08c96190b</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012662 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012662</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Report of NRG Oncology/RTOG 9601, a phase III trial of radiation therapy with or without bicalutamide in patients with PSA elevation following radical prostatectomy for localized carcinoma of the prostate</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012662">66204e12db14eb00b86770c08c9619e4</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 13:58:08</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>aadfbd5edbd0eb00b86770c08c96190b</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">37204252db14eb00b86770c08c96196e</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Prostate</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The study showed that two years of hormone therapy in addition to radiation therapy in patients with prostate cancer reduced the risk of cancer spread and death.&nbsp; &nbsp;The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival and lower incidences of metastatic prostate cancer and death from prostate cancer than radiation therapy plus placebo based on long term follow-up from this phase 3 trial.&nbsp; The median follow-up among the surviving patients was 13 years. The actuarial rate of overall survival at 12 years was 76.3% in the bicalutamide group, as compared with 71.3% in the placebo group (hazard ratio for death, 0.77; 95% confidence interval, 0.59 to 0.99; P=0.04). The 12-year incidence of death from prostate cancer, as assessed by means of central review, was 5.8% in the bicalutamide group, as compared with 13.4% in the placebo group (P&amp;lt;0.001). The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the placebo group (P=0.005). The incidence of late adverse events associated with radiation therapy was similar in the two groups. Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of those in the placebo group (P&amp;lt;0.001).</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28146658</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>be9e79cedb18ab00b86770c08c9619a5</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012622 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012622</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012622">ce0f758edb18ab00b86770c08c9619cc</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:14:42</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>be9e79cedb18ab00b86770c08c9619a5</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">9b0f3902db58ab00b86770c08c961918</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Pancreatic</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The investigators discovered a common mechanism for gemcitabine resistance in pancreatic cancers that involves increased glycolytic flux which leads to glucose addiction.&nbsp; Associated with this is an increase in pyrimidine biosynthesis to boost dCTP levels which, in turn, reduce effect levels of gemcitabine through molecular competition.&nbsp; MUC-1 regulated stabilization of Hif-1alpha appears to mediate the necessary metabolic reprogramming.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>This study was led by investigators at the University of Nebraska Pancreatic Cancer SPORE and involved collaborations with the Weill Cornell Medical College (New York, NY), Harvard Medical School (Boston, MA), Univ. of Texas (Dallas, TX), University of Colorado School of Medicine (Denver, CO), Stony Brook University (Stonybrook, NY), and University of Michigan (Ann Arbor, MI).</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMIDs: 28898700 and 28697341</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>2dafb186db18ab0054d8ff621f9619ea</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012627 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012627</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>New monographs examine current evidence surrounding the economics of tobacco control and tobacco-related health disparities</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012627">d9efb586db18ab0054d8ff621f96199d</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:18:29</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>2dafb186db18ab0054d8ff621f9619ea</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">4eeff586db18ab0054d8ff621f961922</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>The Tobacco Control Research Branch recently released two new monographs as part of the NCI Tobacco Control Monograph Series.&nbsp; Monograph 21: The Economics of Tobacco and Tobacco Control, was produced in collaboration with the World Health Organization.&nbsp; It presents extensive new evidence from low- and middle-income countries and examines global tobacco control efforts since the adoption and entry into force of the World Health Organization Framework Convention on Tobacco Control (WHO FCTC).&nbsp; Monograph 22: A Socioecological Approach to Addressing Tobacco-Related Health Disparities, examines the current evidence surrounding tobacco-related health disparities across the tobacco use continuum&mdash;initiation, secondhand smoke exposure, current use, frequency and intensity, cessation, relapse, morbidity, and mortality&mdash;and the implications for future research and implementation of effective strategies.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCCPS</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>The Monograph 21 is a collaboration with the World Health Organization. NCI is the lead on the monograph.</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://cancercontrol.cancer.gov/brp/tcrb/monographs/index.html">https://cancercontrol.cancer.gov/brp/tcrb/monographs/index.html</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Cancer Control</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>d9384e96db14eb00b86770c08c961906</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012683 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012683</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>NAVIGATE (NCI and VA Group to Increase Trial Enrollment)</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012683">9878ca96db14eb00b86770c08c96194f</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:34:18</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>d9384e96db14eb00b86770c08c961906</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">ad7886d6db14eb00b86770c08c961958</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>NAVIGATE (NCI and VA Group to Increase Trial Enrollment) is a three-year agreement between NCI and the U.S. Department of Veterans Affairs aimed at making it easier for more U.S. veteran patients with cancer to enroll in NCI clinical trials. The program will focus on increasing participation of VA Medical Centers (VAMC) in NCI trials and providing infrastructure funding support to VAMC sites for enrollment of veteran patients into NCTN and NCORP clinical trials. An RFA to support enrollment at 8 VA sites was released on November 15, with awards to be made in spring 2018.&nbsp; The overall goal of this agreement is to ensure sustainable VAMC participation in NCI clinical trials over many years. An executive committee of NCI and VA personnel will oversee activities and help overcome barriers to trial participation at the central and national level.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCCT</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has the lead on this activity</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://www.research.va.gov/programs/csp/NAVIGATE-RFA.pdf">https://www.research.va.gov/programs/csp/NAVIGATE-RFA.pdf</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>e9214ac6db18ab0054d8ff621f9619d5</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012635 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012635</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>NCI launches largest study to date of African-American cancer survivors in the US</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012635">b471cac6db18ab0054d8ff621f9619e0</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:25:16</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>e9214ac6db18ab0054d8ff621f9619d5</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">2d718ec6db18ab0054d8ff621f9619d0</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>In February 2017, NCI launched the Detroit Research on Cancer Survivors (ROCS) study, the largest study to date of African-American cancer survivors in the US.&nbsp; The study leverages the Detroit area population-based cancer registry, which is part of the SEER Program, to identify African Americans who have recently been diagnosed with cancer.&nbsp; A unique aspect of this study is the inclusion of 2,780 family members to help researchers understand how a cancer diagnosis affects the mental, physical, and financial health of those providing care.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCCPS</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>The grant has been awarded to Ann G. Schwartz, Ph.D., M.P.H., deputy center director, and Terrance Albrecht, Ph.D., associate director for Population Sciences of the Wayne State University School of Medicine and the Karmanos&nbsp;</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://www.cancer.gov/news-events/press-releases/2017/detroit-cancer-survivors-study">https://www.cancer.gov/news-events/press-releases/2017/detroit-cancer-survivors-study</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Population Science</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>586c758edb18ab00b86770c08c961903</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012610 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012610</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012610">beac318edb18ab00b86770c08c9619ec</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:04:23</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>586c758edb18ab00b86770c08c961903</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">88bc798edb18ab00b86770c08c961991</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Kidney</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Clear cell renal cell carcinoma (ccRCC) is characterized by BAP1 and PBRM1 mutations, which are associated with tumors of different grade and prognosis. Bap1 and Pbrm1 conditionally targeted in the mouse with Vhl failed to cause tumorigenesis. In contrast, targeting with PAX8, a transcription factor frequently overexpressed in ccRCC, led to ccRCC of different grades. Using ccRCC as a model, the investigators show that Bap1 and Pbrm1 loss drives tumor grade, and that the conversion from low grade to high grade can be promoted by activation of mTORC1.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI UTSW Kidney SPORE</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="PMID:28473526;">PMID:28473526;</a> <a href="PMCID:5540776">PMCID:5540776</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>8d2ca512dbd0eb00b86770c08c9619b9</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012645 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012645</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>Study finds premature death rates diverge in the United States by race and ethnicity</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012645">1b8c6552dbd0eb00b86770c08c96198d</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:51:38</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>a8f07dd2dbd0eb00b86770c08c961993</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">def0b916dbd0eb00b86770c08c96196f</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Dr. Meredith Shiels, Dr. Amy Berrington, Dr. Neal Freedman and colleagues conducted a comprehensive study of premature death rates (i.e., deaths among 25- to 64-year-olds) for the entire U.S. population from 1999 to 2014. They report a strong decline in rates among Hispanics, blacks, and Asian/Pacific Islanders (APIs)&mdash;in line with trends in Canada and the United Kingdom&mdash;but an increase among whites and American Indian/Alaska Natives (AI/ANs). The declines were due mainly to fewer deaths from cancer, heart disease, and HIV over the time period of the study, reflecting successes in public health efforts to reduce tobacco use and medical advances to improve diagnosis and treatment. In contrast, overall premature death rates for whites and AI/ANs were driven up by dramatic increases in deaths from accidents (primarily drug overdoses), as well as suicide and liver disease.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), the National Institute on Drug Abuse, and the University of New Mexico College of Nursing</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28131493</div>
<div>NCI Press Release: <a href="https://www.cancer.gov/news-events/press-releases/2017/premature-death-rates-diverge">https://www.cancer.gov/news-events/press-releases/2017/premature-death-rates-diverge</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>fafff186db18ab0054d8ff621f961907</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012628 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012628</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>NCI launches Cancer Center Cessation Initiative</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012628">1b40c686db18ab0054d8ff621f961909</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:20:15</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>fafff186db18ab0054d8ff621f961907</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">58508e86db18ab0054d8ff621f961933</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>NCI launched the Cancer Center Cessation Initiative, or C3I, as part of the NCI Cancer Moonshotâ  program. The long-term goal of this initiative is to help cancer centers build and implement sustainable tobacco cessation treatment programs to routinely address tobacco cessation with cancer patients.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCCPS</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Funding has been awarded to 22 NCI-designated cancer centers, supported by a scientific coordinating center based at the University of Wisconsin</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://cancercontrol.cancer.gov/brp/tcrb/cessation-initiative.html">https://cancercontrol.cancer.gov/brp/tcrb/cessation-initiative.html</a></div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Cancer Control</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>6cd63d0adb18ab00b86770c08c96196a</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012593 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012593</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Systemic Immunity is Required for Effective Cancer Immunotherapy</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012593">0307b54adb18ab00b86770c08c961936</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:39:49</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>6cd63d0adb18ab00b86770c08c96196a</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">4417318adb18ab00b86770c08c9619f0</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>In a study funded by the NCI Cancer Systems Biology Consortium, Edgar Engleman and colleagues utilized an integrative proteomic analysis of genetically engineered cancer models to demonstrate that systemic immunity, versus a local immune response, is required for an effective response to immunotherapy. By constructing local activation networks through a newly developed computational algorithm termed the Statistical Scaffold Algorithm, Engleman and Garry Nolan identified a peripheral subset of CD4 T cells that were upregulated in a model of triple negative breast cancer that was responsive to immunotherapy. This finding was supported by data from melanoma patients treated with anti-CTLA-4 who also upregulated this cell subset and were responsive to therapy. These findings call attention to the role that the organism-wide immune response plays during treatment with immunotherapy.&nbsp;&nbsp;</div>
<div>&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID 28111070</div>
<div><a href="https://med.stanford.edu/news/all-news/2017/01/bodywide-immune-response-important-for-fighting-cancer.html">https://med.stanford.edu/news/all-news/2017/01/bodywide-immune-response-important-for-fighting-cancer.html</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>7fd4c216db14eb00b86770c08c96192c</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012673 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012673</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>New targets for immunotherapy-based treatment of HPV-related cancers</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012673">7e154ed2db14eb00b86770c08c961968</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:19:44</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>7fd4c216db14eb00b86770c08c96192c</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">24258e16db14eb00b86770c08c96190e</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Immunotherapies designed to treat cancers caused by the human papillomavirus (HPV), including cervical, anal and oropharyngeal cancers, have traditionally targeted protein antigens produced by the virus itself. However, such treatments have so far had little success in the regression of HPV-related cancers. Scientists led by CCR's Christian Hinrich show that immunotherapy treatments that resulted in complete regression of metastatic cervical cancer largely targeted two non-viral antigens.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28408606</div>
<div><a href="https://ccr.cancer.gov/news/article/new-targets-for-immunotherapy-based-treatment-of-HPV-related-cancers">https://ccr.cancer.gov/news/article/new-targets-for-immunotherapy-based-treatment-of-HPV-related-cancers</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>cd3ab58adb18ab00b86770c08c961930</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012601 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012601</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Optimized approach for Ion Proton RNA sequencing reveals details of RNA splicing and editing features of the transcriptome</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012601">238abd8adb18ab00b86770c08c9619d5</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:55:09</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>cd3ab58adb18ab00b86770c08c961930</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">419a7d0edb18ab00b86770c08c961903</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>A new RNA sequencing method to analyze RNA alternative splicing has recently been developed that now provides even coverage across the whole length of an RNA molecule, works on RNA molecules of any length including partially degraded RNAs, and works on very small quantities of RNA.&nbsp; This improved technology allowed Dr. Scott Ness and his team to identify a novel JAK2 mutation in a leukemia patient. This finding resulted in the patient's therapy being modified to include a tyrosine kinase inhibitor, ruxolitinib, which helped the patient achieve remission so that she could undergo a stem cell transplant. This technology advance resulted in a successful patient intervention and could improve the outcomes of other leukemia patients in which this JAK2 mutation can now more easily be identified.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>The NCI Provocative Question R01, R01CA170250 awarded to Scott Ness from the University of New Mexico Health Science Center partially funded this work; Collaborators - Jodi Mayfield and Stuart Winter.</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28459821, PMID: 27860260</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>93fca912dbd0eb00b86770c08c96198a</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012647 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012647</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>Whole-genome sequencing of HPV 16 reveals new criterion for carcinogenicity</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012647">084da552dbd0eb00b86770c08c961906</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:51:54</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>d801b916dbd0eb00b86770c08c961972</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">d601f916dbd0eb00b86770c08c961944</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>There are more than half a million cases of cervical cancer a year worldwide, and human papillomavirus (HPV) type 16 causes about half of all these cases. We don&rsquo;t know why HPV 16 is uniquely highly carcinogenic compared to other HPV types, or why the majority of HPV 16 infections will clear on their own while a few will persist and lead to cervical precancer and cancer. Led by Dr. Lisa Mirabello, investigators observed that a particular genetic sequence of the E7 oncogene is common to virtually all cervical cancers caused by HPV 16 worldwide; demonstrating that the E7 oncoprotein is the fundamental contributor to carcinogenesis. This large genomic analysis shines new light on the influence of viral genetic diversity on carcinogenicity of the high-risk type HPV 16.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), International Agency for Research on Cancer, Kaiser Permanente Northern California Sackler Institute for Comparative Genomics, The Chinese University of Hong Kong, Albert Einstein College of Medicine, University of Oklahoma Health Sciences Center, Fundacion INCIENSA</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28886384</div>
<div>NCI Cancer Currents Blog: <a href="https://www.cancer.gov/news-events/cancer-currents-blog/2017/hpv-viral-gene">https://www.cancer.gov/news-events/cancer-currents-blog/2017/hpv-viral-gene</a>&nbsp;</div>
<div>DCEG Research News Highlight: <a href="https://dceg.cancer.gov/news-events/research-news-highlights/2017/hpv16-e7-genomics">https://dceg.cancer.gov/news-events/research-news-highlights/2017/hpv16-e7-genomics</a>&nbsp;</div>
<div>Cell accompanying article to highlight the work: <a href="http://www.sciencedirect.com/science/article/pii/S0092867417309911?via%3Dihub">http://www.sciencedirect.com/science/article/pii/S0092867417309911?via%3Dihub</a>&nbsp;</div>
<div>Cell press release: <a href="https://www.eurekalert.org/pub_releases/2017-09/cp-hp1083117.php">https://www.eurekalert.org/pub_releases/2017-09/cp-hp1083117.php</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>ae007552dbd0eb00b86770c08c9619bb</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012654 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012654</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>No increased risk of death among U.S. physicians who perform fluoroscopy-guided interventional procedures compared to psychiatrists</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012654">9e407dd2dbd0eb00b86770c08c961944</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:59:11</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>03a23196dbd0eb00b86770c08c961909</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">60b2f196dbd0eb00b86770c08c96198a</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Fluoroscopy-guided interventional (FGI) procedures are often an alternative to more invasive surgeries, resulting in both clinical benefits and lower cost to patients. Some concerns have been raised regarding the potential for occupational exposure to ionizing radiation from repeated administering of these procedures. In a prospective cohort study of U.S. physicians who performed FGI procedures (FGI MDs), Dr. Martha Linet, Dr. Cari Kitahara, Dr. Ruth Kleinerman, Dr. Amy Berrington, and colleagues found no increased risk of death (total and cause-specific) among FGI MDs, compared to physicians who did not perform these types of tests (psychiatrists). Although larger and longer-term follow-up studies must be done to confirm these results, this study suggests that modern safety measures protecting physicians who perform FGI procedures have been effective in preventing radiation-related deaths.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), American Board of Internal Medicine, U.S. Food and Drug Administration, members of the Multi-Specialty Occupational Health Group</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28234559</div>
<div>DCEG Research News Highlight: <a href="https://dceg.cancer.gov/news-events/research-news-highlights/2017/fgimds-vs-psychiatrists">https://dceg.cancer.gov/news-events/research-news-highlights/2017/fgimds-vs-psychiatrists</a>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>9b0cf54edb18ab00b86770c08c96194d</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012608 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012608</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Targeting renal cell carcinoma with a HIF-2 antagonist</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012608">de5cb14edb18ab00b86770c08c961923</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:02:59</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>9b0cf54edb18ab00b86770c08c96194d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">eb5c758edb18ab00b86770c08c961901</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Kidney</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>This group uses a tumor graft/patient-derived xenograft platform to evaluate PT2399, a selective HIF-2 antagonist that was identified using a structure-based design approach. Some VHL-mutant ccRCCs were resistant to PT2399 despite HIF-2 dissociation in tumors and evidence of Hif-2 inhibition. Here a HIF-2-dependent gene signature in sensitive tumors has been identified. Binding site and second site suppressor mutations in HIF-2&alpha; and HIF-1&beta; have been identified. Both mutations preserved HIF-2 dimers despite treatment with PT2399.</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI UTSW Kidney SPORE</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="PMID:27595394">PMID:27595394</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>f5beb546db18ab0054d8ff621f9619c5</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012621 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012621</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>SBIR Funded Research Tool Used by over 5,000 Academic Institutions and close to 1,000 peer-reviewed publications in 2017</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012621">3cee7146db18ab0054d8ff621f961927</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:14:04</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>f5beb546db18ab0054d8ff621f9619c5</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">15eef946db18ab0054d8ff621f96195a</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>NCI-SBIR Funded Advanced Cell Diagnostics developed the RNAscope technology which is being highly used by in academic research.&nbsp; The number of peer-reviewed publications that used RNAscope nearly doubled each year for the first 6 years it was marketed, being used in close to 1,000 publications in 2017.&nbsp; RNAscop uses novel multiplex nucleic acid in situ hybridization technology for single molecule detection of RNA/DNA within intact cells while maintaining cell morphology.&nbsp; Advanced Cell Diagnostics was acquired by Biotechne in 2016 for $325MM.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>SBIR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>SBIR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://acdbio.com/bio-techne-announces-agreement-acquire-advanced-cell-diagnostics">https://acdbio.com/bio-techne-announces-agreement-acquire-advanced-cell-diagnostics</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>90ac6552dbd0eb00b86770c08c96198f</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012646 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012646</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>NCI study shows feasibility of cancer screening protocol for patients with Li-Fraumeni syndrome</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012646">daec2952dbd0eb00b86770c08c9619db</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:54:55</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>60b13156dbd0eb00b86770c08c96194d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">16b17556dbd0eb00b86770c08c961978</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Rare</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>NCI researchers led by Dr. Sharon Savage found a higher than expected prevalence of cancer at baseline screening of individuals with Li-Fraumeni syndrome (LFS), a rare inherited disorder that leads to a higher risk of developing certain cancers. The findings demonstrate the feasibility of whole-body MRI as a comprehensive cancer screening protocol for this high-risk population. A companion meta-analysis, published in the same issue of JAMA Oncology, is the result of an international collaboration and confirms the findings of the study conducted at NCI.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), NIH Clinical Center</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28772286</div>
<div>NCI Press Release: <a href="https://www.cancer.gov/news-events/press-releases/2017/li-fraumeni-syndrome-screening-study?cid=soc_tw_en_NCIMedia_press-release_screening_pt">https://www.cancer.gov/news-events/press-releases/2017/li-fraumeni-syndrome-screening-study?cid=soc_tw_en_NCIMedia_press-release_screening_pt</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>28bc798edb18ab00b86770c08c961993</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012611 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012611</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012611">9c1db54edb18ab00b86770c08c9619fb</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:06:07</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>28bc798edb18ab00b86770c08c961993</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">9d1dbd8edb18ab00b86770c08c961957</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Prostate</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Using in vitro and in vivo human prostate cancer models this study revealed that tumors can develop resistance to the enzalutamide, a second-generation anti-androgen, by a phenotypic shift from androgen receptor (AR) dependent luminal epithelial cells to AR-independent basal-like cells. This lineage plasticity, which occurs with the functional loss TP53 and RB1, was found to be enabled by SOX2 expression and could be reversed by restoring the function of TP53 and RB1 or by inhibiting SOX2 expression.&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Other supporting agencies included the Congressionally Directed Medicl Research Programs Prostate Cancer Research Program, the Howard Hughes Medical Institute, the American Association for Cancer Research, the Prostate Canceer Foundation, the Starr Cancer Consortium, the European Research Council, the Damon Runyon Cancer Research Foundation.&nbsp;</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="PMID:28059768">PMID:28059768</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>67143596dbd0eb00b86770c08c96194a</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012658 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012658</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>The Nursing Postdoctoral Program in Cancer and Health Disparities</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012658">e864fd96dbd0eb00b86770c08c961966</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 13:06:40</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>67143596dbd0eb00b86770c08c96194a</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">996479d6dbd0eb00b86770c08c961938</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>NCI continued to support University of Massachusetts Boston (UMass Boston) and Dana Farber/Harvard Cancer (DFHCC) Nursing Post-Doctoral Fellowship Program. This innovative program was jointly launched by UMass/DFHCC partnership to ensure a diverse and highly trained workforce to meet the national need for highly skilled nursing faculty and researchers committed to better understand and address cancer health disparities. This program was the first of its kind in the country and addresses the critical need to increase the number of nurse scientists trained in cancer and health disparities and to develop a new model for preparing nurse scientists to conduct independent research in cancer disparities. The program is the only nursing post-doctoral program developed by any College/School of Nursing and a clinical partner. It is also the only program offered which focuses on oncology care, research, health disparities, and health policy.&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CRCHD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="http://www.dfhcc.harvard.edu/fileadmin/media/IECD/U54_Nursing_Post-Doctoral_Fellowship_-_2017.pdf">http://www.dfhcc.harvard.edu/fileadmin/media/IECD/U54_Nursing_Post-Doctoral_Fellowship_-_2017.pdf</a>&nbsp;</div>
<div>PMID: 25771193</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Career Development Programs</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>bee9350edb18ab00b86770c08c961905</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012599 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012599</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012599">c32af50edb18ab00b86770c08c961932</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:53:29</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>bee9350edb18ab00b86770c08c961905</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">2c3af50edb18ab00b86770c08c9619d3</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Research supported by a recent R35 award outlined an important mechanism for regulation of mTORC1, a key effector in cancer, metabolism, and injury.&nbsp; The regulation involves a novel polypeptide encoded by the long non-coding RNAs (lncRNA) LINC00961.&nbsp; lncRNAs are non-protein-coding transcripts but recent studies revealed that a segment of their small open reading frames can be translated to polypeptides with unknown significance.&nbsp; The findings from this study outline a unique way for the fine-tuning of mTORC1 in cell- and tissue-specific manners and that lncRNA-encoded polypeptides are not translational noise but functionally relevant peptides with potential therapeutic significance.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28024296</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>2dc74e96db14eb00b86770c08c9619e7</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012682 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012682</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukemia: a multicentre, first-in-human, open-label, phase 1-2 study</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012682">13284696db14eb00b86770c08c961998</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:33:08</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>2dc74e96db14eb00b86770c08c9619e7</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">7838c2d6db14eb00b86770c08c961901</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Leukemia</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Internal tandem duplication mutations in FLT3 are common in acute myeloid leukemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukemia has been limited by rapid generation of resistance mutations, particularly in codon Asp835 (D835). The investigators aimed to assess the highly selective oral FLT3 inhibitor gilteritinib in patients with relapsed or refractory acute myeloid leukemia. 252 adults with relapsed or refractory acute myeloid leukemia received oral gilteritinib once daily in one of seven dose-escalation (n=23) or dose-expansion (n=229) cohorts. gilteritinib was well tolerated. 100 (40%) of 249 patients in the full analysis set achieved a response, with 19 (8%) achieving complete remission, ten (4%) complete remission with incomplete platelet recovery, 46 (18%) complete remission with incomplete hematological recovery, and 25 (10%) partial remission. Based on activity data, gilteritinib at 120 mg/day is being tested in phase 3 trials.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>MDACC Leukemia SPORE</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="PMID:28645776">PMID:28645776</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>cb298ed6db14eb00b86770c08c9619f6</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012686 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012686</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>National Clinical Trials Network (NCTN) NCORP Data Archive</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012686">5e69cad6db14eb00b86770c08c961962</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:38:32</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>cb298ed6db14eb00b86770c08c9619f6</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">6f69821adb14eb00b86770c08c9619c9</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>NCI has created a centralized, controlled-access database, called the NCTN/NCORP Data Archive. This archive will be used to store and share datasets generated from clinical trials of the National Clinical Trials Network (NCTN) and make these datasets available in a timely manner, on appropriate terms and conditions, to researchers who wish to analyze the data in secondary studies to enhance the public health benefit of the original work. With the goals of meeting both the NIH data sharing policy and NCTN/NCORP program guidelines, the archive increases NCI&rsquo;s data sharing activities that focus mainly on genetic and genomic data into patient-level clinical trial data. With open data, more knowledge can be gained from clinical trials which results in a greater impact on patient care.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CBIIT</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>RAB, CTEP, DCTD (Sherry Ansher); OD, DCTD, NCI (Jason Cristofaro) ; BRP, DCTD, NCI (Edward Korn, PhD);&nbsp; BRP, NCI (Lisa McShane, PhD);&nbsp; DCP, NCI (Worta McCaskill-Stevens, MD);&nbsp; CIB, CTEP, DCTD, NCI (Margaret Mooney, MD); CBIIT, NCI (David Patton);&nbsp; EMMES Corporation (Rebecca Enos, Tudor Maican); Leidos (Kumar Kuntipuram,&nbsp; Jason Luttrel, Barry Alkis)</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://nctn-data-archive.nci.nih.gov/">https://nctn-data-archive.nci.nih.gov/</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>8e364656db14eb00b86770c08c961921</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012678 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012678</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>SBIR-Funded G-Rex technology technologies for cutting-edge therapies</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012678">c076c656db14eb00b86770c08c9619f3</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:25:33</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>8e364656db14eb00b86770c08c961921</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">6176ce56db14eb00b86770c08c9619a4</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The cell therapy market continues to quickly expand and is expected to grow at a rate of over 20% per year for the next five years.&nbsp; The increase in market growth is in part because of new technologies enabling rapid expansion of cells during the manufacturing process.&nbsp; The NCI SBIR Program funded one of the few available cell expansion technologies that support large-scale cell expansion, Wilson Wolf Manufacturing, who developed the G-Rex platform with NCI SBIR funding.&nbsp; The G-Rex platform is currently being utilized in seven separate clinical trials.&nbsp; One cell therapy that requires rapid in-vitro expansion is CAR-T cell therapies.&nbsp; The FDA approved the first two CAR-T therapies in 2017, and clinicaltrials.gov has 415 current clinical trials listed for CAR-T cells.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>SBIR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI SBIR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://clinicaltrials.gov/ct2/results?cond=&amp;term=CAR-T&amp;cntry1=&amp;state1=&amp;Search=Search">https://clinicaltrials.gov/ct2/results?cond=&amp;term=CAR-T&amp;cntry1=&amp;state1=&amp;Search=Search</a></div>
<div><a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm</a></div>
<div><a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm</a></div>
<div><a href="http://www.businesswire.com/news/home/20170919005788/en/Global-Cell-Therapy-Market-Report-2017-2021--">http://www.businesswire.com/news/home/20170919005788/en/Global-Cell-Therapy-Market-Report-2017-2021--</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>467886d6db14eb00b86770c08c961965</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012684 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012684</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Reimagining clinical trials search functionality on trials.cancer.gov</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012684">dec88e96db14eb00b86770c08c961983</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:35:49</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>467886d6db14eb00b86770c08c961965</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">7bc8cad6db14eb00b86770c08c961920</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The Cancer Clinical Trials Search on trials.cancer.gov now directly uses information from NCI's Clinical Trials Reporting Program database (CTRP) through a public Clinical Trials Search (CTS) Application Programming Interface (API). This cross-NCI effort drew on expertise to modify the CTS-API to support the complex requirements for advanced search capability, including the development of a simplified representation of NCI&rsquo;s Thesaurus for disease and drug ontologies made available through a new Enterprise Vocabulary Services (EVS) API. Improvements to the user interface on trials.cancer.gov brings clinical trial information in a logical manner to more providers, patients, and their family members. Together, the CTS- and EVS-APIs have reimagined clinical trials searching, supporting standardized language and data elements to enhance functionality and utility for users. The APIs make these data available for the broad communityâ&mdash;âadvocacy groups, academia, and others in the cancer clinical trials ecosystem, and enables these groups to build applications, integrations, search tools, and digital platforms tailored to individual needs.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCCT, CBIIT</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI/Coordinating Center for Clinical Trials is the lead (Samantha Finstad.)&nbsp; Collaborators include NCI/Center for Biomedical Informatics and Information Technology (Larry Wright) and NCI/Office of Communications and Public Liaison (Kevin Broun)</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search</a> <a href="https://clinicaltrialsapi.cancer.gov/">https://clinicaltrialsapi.cancer.gov/</a></div>
<div><a href="https://evs.nci.nih.gov/ftp1/NCI_Thesaurus/CTS_API_Disease_Category_Terminology/">https://evs.nci.nih.gov/ftp1/NCI_Thesaurus/CTS_API_Disease_Category_Terminology/</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>9c9bf54edb18ab00b86770c08c96199f</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012606 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012606</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012606">b50cf54edb18ab00b86770c08c9619a4</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:01:34</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>9c9bf54edb18ab00b86770c08c96199f</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">760c318edb18ab00b86770c08c9619e9</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Somatic mutations in spliceosome genes are detectable in &sim;50% of patients with myelodysplastic syndromes (MDS). Here the investigators utilize sudemycin compounds that modulate pre-mRNA splicing. Hematopoietic cells expressing mutant U2AF1(S34F), including primary patient cells, had an increased sensitivity to in vitro sudemycin treatment relative to controls. The data suggest a potential for treating hematological cancers harboring U2AF1 mutations with pre-mRNA splicing modulators like sudemycins.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>WU Leukemia SPORE</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="PMID:28067246">PMID:28067246</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>edf04a52db14eb00b86770c08c96193c</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012665 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012665</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012665">19514652db14eb00b86770c08c961936</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:03:14</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>edf04a52db14eb00b86770c08c96193c</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">e6518e52db14eb00b86770c08c9619a8</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Colon/colorectal</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>This prospective, international meta-analysis of international trials failed to demonstrate that 3 months of adjuvant therapy was non-inferior to 6 months however, the test for interaction was statistically significant relative to CAPOX vs FOLFOX.&nbsp; 3 months of CAPOX was non-inferior to 6 months especially for lower risk patients but 3 months of FOLFOX was inferior to 6 months especially for higher risk patients.&nbsp; These data provide a framework for discussions on risks and benefits of individualized adjuv therapy approaches.&nbsp; The analysis included 12,834 pts from 12 countries. Stage distribution for colon cancer patients: 13% T1-2, 66% T3, 21% T4; 28% N2; 40% received XELOX. Grade 3+ neurotoxicity was higher in the 6 vs 3 month arm (16 v 3% FOLFOX, 9 v 3% XELOX, p&amp;lt;0.0001). With a median follow-up of 39 mos, 3,263 disease-free survival (DFS) events were observed.&nbsp; Overall, the 3 year DFS rate was 74.6% (3m) and 75.5% (6-month therapy arm), with estimated DFS hazard ratio of 1.07 (95%CI, 1.00-1.15). The 3-month versus 6-month DFS hazard ratios were 1.16 (95%CI, 1.06-1.26) and 0.95 (95% CI, 0.85-1.06) for FOLFOX and XELOX treated patients, respectively. The 3-month versus 6-month DFS hazard ratios were 1.01 (95%CI, 0.90-1.12) in T1-3 N1 patients, and 1.12 (95%CI, 1.03-1.23) for T4 or N2 patients.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<div>This was a prospectively planned, international meta-analysis which was led by the National Cancer Institute supported NCTN Group (Alliance) with international partners.</div>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>Qian S, Sobrero AF, and Shields AF et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.&nbsp; ASCO 2017 - Late Breaking Abstract, J Clin Oncol 35, 2017 (suppl; abstr LBA1).</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>fb590986db94ab00b86770c08c961966</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012584 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012584</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>TARGET initiative identified novel pediatric cancer "drivers" and resistance markers</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012584">04f9c186db94ab00b86770c08c9619f3</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 15:22:44</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>fb590986db94ab00b86770c08c961966</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:25</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">120f85cadb94ab00b86770c08c961988</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Pediatric, Rare</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Treatment of pediatric cancer patients, while successful in 80% of patients is associated with very high co-morbidity.&nbsp; The TARGET project was established to identify the drivers of tumor development, progression and relapse.&nbsp; While there is some overlap with alterations involved in adult cancers, TARGET identified other cancer-relevant alterations that are either only found in children or present at a much higher frequency than in adults.&nbsp; During this past year, novel drivers were found for T-cell ALL cases and Wilms tumor.&nbsp; In addition, under this initiative it was found that a miRNA-signature is predictive for poor outcome of AML patients.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Office of Cancer Genomics led the effort together w/ CTEP, NCI; NCI collaborates with the Children's Oncology Group.&nbsp; Each disease has its own COG PI(s), see TARGET web site.</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29068783,">https://www.ncbi.nlm.nih.gov/pubmed/29068783,</a> <a href="https://www.ncbi.nlm.nih.gov/pubmed/28825729,">https://www.ncbi.nlm.nih.gov/pubmed/28825729,</a> <a href="https://www.ncbi.nlm.nih.gov/pubmed/28671688;">https://www.ncbi.nlm.nih.gov/pubmed/28671688;</a> <a href="https://www.ncbi.nlm.nih.gov/pubmed/27702824;">https://www.ncbi.nlm.nih.gov/pubmed/27702824;</a> <a href="https://ocg.cancer.gov/programs/target;">https://ocg.cancer.gov/programs/target;</a> <a href="https://www.nature.com/articles/nrneph.2017.131;">https://www.nature.com/articles/nrneph.2017.131;</a> <a href="http://www.natureasia.com/en/nmiddleeast/article/10.1038/nmiddleeast.2017.135">http://www.natureasia.com/en/nmiddleeast/article/10.1038/nmiddleeast.2017.135</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>22d4710adb18ab00b86770c08c9619fa</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012589 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012589</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Cryo-EM images capture CRISPR's interaction with target DNA</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012589">9f35b9c6db18ab00b86770c08c96193a</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:31:55</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>22d4710adb18ab00b86770c08c9619fa</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">81553d0adb18ab00b86770c08c961943</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Using cryo-EM, researchers led by CCR's Sriram Subramaniam, have captured a series of highly detailed images of a protein complex belonging to the CRISPR system that can be used by bacteria to recognize and destroy foreign DNA. The images reveal the molecule&rsquo;s form before and after its interaction with DNA and help illuminate both how the complex functions and how it can be blocked.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28985564</div>
<div><a href="https://ccr.cancer.gov/news/article/Watching-the-action-unfold-new-cryo-em-images-capture-crispr-interaction-with-target-dna">https://ccr.cancer.gov/news/article/Watching-the-action-unfold-new-cryo-em-images-capture-crispr-interaction-with-target-dna</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>64f242d2db14eb00b86770c08c9619a0</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012668 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012668</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012668">c73342d2db14eb00b86770c08c9619fd</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:11:33</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>64f242d2db14eb00b86770c08c9619a0</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">5b534ad2db14eb00b86770c08c9619da</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Leukemia</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Although allogeneic hematopoietic cell transplant (allo-HCT) is used to treat patients with high-risk chronic lymphocytic leukemia (CLL), 5-year overall survival is 38%, most deaths due to post-transplant relapse.&nbsp; This study examined the Bruton&rsquo;s tyrosine kinase (BTK) and interleukin-2 inducible kinase (ITK) inhibitor ibrutinib in patients with relapsed CLL and found that of 27 patients a high percentage achieved an overall response (83% in the multi-institutional cohort, with minimal residual disease negativity achieved in 4/11 patients examined), with no increase in graft-versus host disease.&nbsp;</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMCID: PMC5179333</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>b92d71c2db18ab0054d8ff621f961936</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012614 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012614</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Collaborative Consortia for the Study of HIV-Associated Cancers: U.S. and Low-and Middle-Income Country Partnerships (U54).Â </short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012614">e97df906db18ab0054d8ff621f961981</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:07:50</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>b92d71c2db18ab0054d8ff621f961936</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">9a7d3d06db18ab0054d8ff621f96190e</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>HIV-positive individuals are now living longer and aging with HIV, it is expected that cancer will continue to be a significant comorbidity and cause of death. This initiative will support research projects that address questions in HIV-associated malignancies that are high priority to the partnering Low- and Middle Income Country (LMIC).&nbsp; Three U54 applications were funded: UM CFAR SCCC/Argentina Consortium for research and training in Virally Induced AIDS Malignancies; Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria and; The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP). These consortia will also enhance research capacity at the LMIC institution(s) as well as facilitate the professional development of investigators from the LMICs. This initiative complements a previous initiative that established the sub-Saharan African Collaborative HIV and Cancer Consortia which funded eight consortia.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>OHAM</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>OHAM was the lead with support from the Fogarty International Center</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-16-018.html;">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-16-018.html;</a></p>
<p><a href="https://www.cancer.gov/about-nci/organization/oham/hiv-aids-research/oham-research/research-africa">https://www.cancer.gov/about-nci/organization/oham/hiv-aids-research/oham-research/research-africa</a>&nbsp;</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>ef4f2992dbd0eb00b86770c08c961914</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012652 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012652</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>Increasing thyroid cancer incidence and mortality in the United States</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012652">5a9f2992dbd0eb00b86770c08c96195e</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:58:45</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>2c923196dbd0eb00b86770c08c9619da</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">d6927196dbd0eb00b86770c08c96196b</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Thyroid</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Dr. Cari Kitahara and colleagues were the first to report an in-depth analysis of thyroid cancer incidence and mortality trends in the United States. They observed significant increases in both incidence and mortality overall, and for patients diagnosed with advanced-stage papillary thyroid cancer (PTC). These results suggest that changes in the prevalence of environmental risk factors have led to a true increase in thyroid cancer incidence and mortality, and challenge the prevailing notion that rising rates have been due entirely to increased detection and diagnosis of non-aggressive PTC. Thyroid cancer is now the eighth most common cancer diagnosis in the United States.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), Duke University Medical Center</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28362912</div>
<div>DCEG Research News Highlight: <a href="https://dceg.cancer.gov/news-events/research-news-highlights/2017/thyroid-trends">https://dceg.cancer.gov/news-events/research-news-highlights/2017/thyroid-trends</a>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>70c6c216db14eb00b86770c08c9619e2</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012679 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012679</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012679">7e07ce56db14eb00b86770c08c96192e</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:28:12</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>70c6c216db14eb00b86770c08c9619e2</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">40174696db14eb00b86770c08c961975</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Prostate, Metastatic</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>This study shows that clinically informative genomic profiling of cell-free DNA from minimally invasive blood sampling is feasible in nearly all patients with metastatic CRPC.&nbsp; Using plasma samples from patient cohorts, cfDNA sequencing showed an association of genomic changes in baseline cfDNA with disease progression and dynamic cfDNA changes associated with enzalutamide resistance. At time of progression, cfDNA sequencing revealed mutations or copy number changes in all patients tested, including clinically actionable alteration in DNA damage repair genes and PI3K pathway genes.&nbsp; The results demonstrate that there is strong potential for the practical implementation of cfDNA sequencing into precision medicine programs in advanced prostate cancer.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Lead authors were supported through a Pilot Project Award from the Pacific Northwest Prostate Cancer SPORE. Other support was received from a Canadian Cancer Society Research Institute Innovation Grant, a Terry Fox New Frontiers Program Project Grant, a Prostate Cancer Canada Movember Discovery Grant, the National Health and Medical Research Council CJ, a Martin Overseas Biomedical Fellowship, Canadian Urologic Oncology Research Award, and the Emil Aaltonen foundation.</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 27148695</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>87654a16db14eb00b86770c08c9619b0</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012675 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012675</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Early-phase trial demonstrates shrinkage in pediatric neural tumors</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012675">3da58e16db14eb00b86770c08c9619a3</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:22:06</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>87654a16db14eb00b86770c08c9619b0</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">87a54656db14eb00b86770c08c961908</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Pediatric, Rare</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Plexiform neurofibromas develop in up to 50 percent of people with NF1. The majority of these tumors, which can cause significant pain, disability, and disfigurement, are diagnosed in early childhood and grow most rapidly prior to adolescence. Complete surgical removal of the tumors is rarely feasible, and incompletely resected tumors tend to grow back. In an early-phase clinical trial of a new oral drug, selumetinib, children with NF1 and plexiform neurofibromas tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. The study took advantage of techniques developed by CCR's Brigitte Widemann that enabled very precise measurement. This type of long term study (15 year follow up) required long term investment of the intramural research program to complete.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28029918</div>
<div><a href="https://www.cancer.gov/news-events/press-releases/2016/selumetinib-shrinks-pediatric-tumors">https://www.cancer.gov/news-events/press-releases/2016/selumetinib-shrinks-pediatric-tumors</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>8ff18a82db58ab00b86770c08c9619c7</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012639 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012639</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Identification of genes required for successful immunotherapy</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012639">63224682db58ab00b86770c08c961931</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:28:27</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>8ff18a82db58ab00b86770c08c9619c7</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">70328e82db58ab00b86770c08c96191e</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>A study conducted by CCR's Nickolas Restifo identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don&rsquo;t respond to immunotherapy or respond initially but then stop as tumor cells develop resistance to immunotherapy. The list of genes generated from this study could serve as a blueprint to study the emergence of tumor resistance to T cell-based cancer therapies.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28783722</div>
<div><a href="https://www.nih.gov/news-events/news-releases/nci-study-identifies-essential-genes-cancer-immunotherapy">https://www.nih.gov/news-events/news-releases/nci-study-identifies-essential-genes-cancer-immunotherapy</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>9ba14282db58ab00b86770c08c9619f6</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012638 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012638</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Liver Cancer Subtypes</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012638">e4e14e02db58ab00b86770c08c9619e1</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:27:10</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>9ba14282db58ab00b86770c08c9619f6</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">39e1ca82db58ab00b86770c08c961927</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Liver</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>A comprehensive molecular analysis of two types of liver cancer, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), has identified common molecular subtypes that can be found among patients with either disease. Although HCC and ICC are considered separate diseases, the finding suggests that a unified clinical approach could benefit patients with both types of liver cancer.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR, Thailand Initiative for Genomics and Expression Research in Liver Cancer (TIGER-LC) including Her Royal Highness Princess Chulabhorn Mahidol of Thailand, Ph.D.</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28648284</div>
<div><a href="https://ccr.cancer.gov/news/article/molecular-profiles-suggest-two-types-of-liver-cancer-should-be-treated-as-one">https://ccr.cancer.gov/news/article/molecular-profiles-suggest-two-types-of-liver-cancer-should-be-treated-as-one</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>2232420adb18ab0054d8ff621f961995</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012641 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012641</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Data sharing collaboration between ASCO and NCI's SEER Program to offer insights to support clinical care, augment quality improvement and enrich research capabilities</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012641">9c824a0adb18ab0054d8ff621f961967</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:29:52</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>2232420adb18ab0054d8ff621f961995</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">41820e0adb18ab0054d8ff621f961901</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>ASCO held a press event on June 3rd, at their Annual Meeting, to announce the ASCO CancerLinQ&reg; - SEER Program Partnership.&nbsp; The partnership will facilitate the exchange of information between CancerLinQ&reg; participating oncology practices and NCI&rsquo;s Surveillance, Epidemiology, and End Results (SEER) Program.&nbsp; CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. SEER is the primary source of data on cancer incidence and survival in the US.&nbsp; This data sharing effort is intended to enhance the completeness and richness of both data resources.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCCPS</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>American Society of Clinical Oncology (ASCO)</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://www.asco.org/about-asco/press-center/news-releases/cancerlinq-and-national-cancer-institute-announce-partnership">https://www.asco.org/about-asco/press-center/news-releases/cancerlinq-and-national-cancer-institute-announce-partnership</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Population Science</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>62a30ed2db14eb00b86770c08c9619ef</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012670 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012670</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Endoxifen from Bench to Bedside with NCI Support</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012670">2634c2d2db14eb00b86770c08c96198d</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:15:53</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>62a30ed2db14eb00b86770c08c9619ef</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">9844c216db14eb00b86770c08c961977</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Breast</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Although tamoxifen was an effect drug treatment, it did not work for some women with ER-positive breast cancer.&nbsp; Mayo Clinic proposed that the discrepancy may be due to how tamoxifen was processed in the body.&nbsp; NCI funded studies and support from NCI staff lead to discovery of why this phenomenon occurs to a potential drug candidate, endoxifen which inhibits estrogen up to 100 times more strongly than tamoxifen.&nbsp; A randomized phase II clinical trial comparing endoxifen and tamoxifen is ongoing with anticipated results in early 2018.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Mayo Clinic (Rochestor) Breast SPORE P50CA116201</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2017/endoxifen-breast-cancer-NCI-support">https://www.cancer.gov/news-events/cancer-currents-blog/2017/endoxifen-breast-cancer-NCI-support</a></div>
<div>Clinicaltrials.gov ID NCT02311933</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>af418242db58ab00b86770c08c96196d</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012636 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012636</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Epigenetic Screen Identifies SETD8 as a target in High-Risk Neuroblastoma</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012636">70914682db58ab00b86770c08c96192c</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:25:49</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>af418242db58ab00b86770c08c96196d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">92910a82db58ab00b86770c08c961909</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Neuroblastoma</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Despite intense treatment, current therapy for neuroblastoma is still inadequate for 50 percent of high-risk patients and causes significant toxicities. There are limited targeted drugs for this type of cancer, so identifying molecular inhibitors to block tumor growth is an important goal for cancer researchers. Pre-clinical research by CCR's Carol Thiele has identified a number of novel epigenetic targets for high-risk neuroblastoma and validated a promising new targeted inhibitor in pre-clinical models.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28073004</div>
<div><a href="https://ccr.cancer.gov/news/article/novel-target-for-high-risk-neuroblastoma-identified-in-pre-clinical-research">https://ccr.cancer.gov/news/article/novel-target-for-high-risk-neuroblastoma-identified-in-pre-clinical-research</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>6c96f94adb18ab00b86770c08c96192d</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012592 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012592</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Development of the International Cancer Proteomics Consortium (ICPC)</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012592">83c67d4adb18ab00b86770c08c961945</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:38:43</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>6c96f94adb18ab00b86770c08c96192d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">4cd67d4adb18ab00b86770c08c9619af</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>The International Cancer Proteogenome Consortium (ICPC), is a voluntary scientific organization that provides a forum for collaboration (standardization and sharing of resources) among some of the world's leading cancer and proteogenomic research centers. As part of its coordination efforts, cancer types studied by each team is of clinical significance to that country with each team assuming responsibility for their specific cancers.&nbsp; ICPC teams have pledged to make their proteogenomic research datasets available to the public to advance cancer research and care (Data Sharing Pledge).&nbsp; Launched in 2016, as part of the Beau Biden Cancer Moonshot initiative, ICPC facilitates international cooperation to represent the great international diversity of populations, of people, and of cancers.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CSSI</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://obamawhitehouse.archives.gov/the-press-office/2016/09/21/fact-sheet-united-nation-foundations-social-good-summit-vice-president">https://obamawhitehouse.archives.gov/the-press-office/2016/09/21/fact-sheet-united-nation-foundations-social-good-summit-vice-president</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>bfa54256db14eb00b86770c08c96196d</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012676 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012676</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>HPV Serology Standards Laboratory</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012676">dae5c656db14eb00b86770c08c9619da</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:23:14</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>bfa54256db14eb00b86770c08c96196d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">57e50a56db14eb00b86770c08c961947</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The Human Papillomavirus Serology Standards Laboratory (HPV-SSL) is jointly supported by the NCI and the Bill and Melinda Gates Foundation and was established in January 2017. The HPV Serology Standards lab is part of an international initiative to standardize and harmonize serological assays for HPV antibody testing in the context of vaccine trials. Serology standardization is particularly important as new HPV prophylactic vaccine trials are proposing to use serology data as endpoints for licensure of new vaccine indications or new vaccines. The main goals of the Laboratory include the development of qualified secondary assay standards, critical reagents (HPV Virus-Like Particles) and assays that will be made available to the scientific community. Overall, this initiative will enable comparisons of data across different vaccines and different studies and thus, it will facilitate vaccine development and implementation of new vaccine indications and new vaccine candidates.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CSSI</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>National Cancer Institute, Bill and Melinda Gates Foundation, Center for Disease Control, Karolinska Institute, and Public Health England</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://frederick.cancer.gov/news/new-hpv-serology-laboratory-aims-standardize-assays-and-contribute-vaccine-implementation-and">https://frederick.cancer.gov/news/new-hpv-serology-laboratory-aims-standardize-assays-and-contribute-vaccine-implementation-and</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>337db1cedb18ab00b86770c08c9619d6</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012616 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012616</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012616">c5edf1cedb18ab00b86770c08c9619a5</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:09:43</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>337db1cedb18ab00b86770c08c9619d6</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">26ed79cedb18ab00b86770c08c961971</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Breast</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Understanding the molecular nature of resistance to HER-2 targeted therapies could improve breast cancer therapies. Although PIK3CA mutations are associated with resistance to HER2-targeted therapies, HER2+/PIK3CAH1047R transgenic mammary tumors respond to PI3K inhibitor buparlisib (TPB). Researchers sought to identified mechanisms of resistance to combined inhibition of HER2 and PI3K. Data suggest that upregulation of collagen/integrin/Src signaling contributes to resistance to combinatorial HER2 and PI3K inhibition.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Vanderbilt Breast SPORE P50CA098131</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28396358; PMCID: PMC5482178</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>cc5ffd06db18ab0054d8ff621f96193b</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012625 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012625</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Cancer death rates higher in rural areas than in urban areas in the United States</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012625">949ffd46db18ab0054d8ff621f96190a</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:17:02</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>cc5ffd06db18ab0054d8ff621f96193b</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">619f7186db18ab0054d8ff621f9619c8</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Two studies put a spotlight on disparities that have received less attention: those in rural communities across the country. The studies&mdash;one by DCCPS researchers and one led by researchers from the Centers for Disease Control and Prevention (CDC) using DCCPS SEER data&mdash;found that cancer death rates are higher in rural areas than in urban areas. The CDC study also showed that, although cancer deaths rates are decreasing in rural areas, they are doing so more slowly than they are in urban areas.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCCPS</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>One of the two studies cited above (published in MMWR) was led by CDC, relying on NCI-funded data</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://www.cdc.gov/mmwr/volumes/66/ss/ss6614a1.htm">https://www.cdc.gov/mmwr/volumes/66/ss/ss6614a1.htm</a></div>
<div><a href="http://cebp.aacrjournals.org/content/early/2017/06/09/1055-9965.EPI-17-0092">http://cebp.aacrjournals.org/content/early/2017/06/09/1055-9965.EPI-17-0092</a>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Cancer Control</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>3bf23996dbd0eb00b86770c08c961924</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012656 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012656</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Creation of a new transition award to encourage outstanding graduate students to commit to pursuing independent research careers: The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012656">e0a3fd96dbd0eb00b86770c08c96193d</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 13:03:23</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>3bf23996dbd0eb00b86770c08c961924</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">2da3fd96dbd0eb00b86770c08c9619c9</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>The F99/K00 provides late-stage predoctoral students with funding to complete their dissertation research (F99 phase) and 4 years of cancer-focused postdoctoral training at a US-based institution of their choosing (K00 phase). This transition award offers an early start to a career path as an independent researcher, which is being viewed as a less viable option due to reductions in both tenure-track positions and grant funding.&nbsp; The F99/K00 program is being adapted by several other ICs that recognize the need to recruit and retain the best students pursuing independent research careers.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCCT</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI Office of the Director &amp; Center for Cancer Training&nbsp;</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>NCI F99 web page: <a href="https://www.cancer.gov/grants-training/training/funding/f99">https://www.cancer.gov/grants-training/training/funding/f99</a>&nbsp; &nbsp;</p>
<p>FY17 FOA: <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-014.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-014.html</a>&nbsp; &nbsp;</p>
<p>Sample FY17 awardee press releases:</p>
<p><a href="https://medicine.uiowa.edu/pathology/content/madelyn-espinosa-cotton-received-nih-nci-f99k00-fellowship-award-entitled-targeting;">https://medicine.uiowa.edu/pathology/content/madelyn-espinosa-cotton-received-nih-nci-f99k00-fellowship-award-entitled-targeting;</a>&nbsp;</p>
<p><a href="https://bmcb.cornell.edu/maria-liberti-awarded-national-cancer-institute-f99k00-fellowship/;">https://bmcb.cornell.edu/maria-liberti-awarded-national-cancer-institute-f99k00-fellowship/;</a>&nbsp;</p>
<p><a href="https://biomedicalprograms.georgetown.edu/external-fellowships-awards/stephen-devito">https://biomedicalprograms.georgetown.edu/external-fellowships-awards/stephen-devito</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Career Development Programs</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>d6df7d02db58ab00b86770c08c961983</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012629 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012629</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>IAP antagonists induce anti-tumor immunity in multiple myeloma</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012629">3d508242db58ab00b86770c08c961923</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:20:26</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>d6df7d02db58ab00b86770c08c961983</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">53504a42db58ab00b86770c08c96190c</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Multiple myeloma</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Small-molecule IAP (inhibitors of apoptosis) antagonists have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma (MM), resulting in constitutive activation of the noncanonical nuclear factor (NF)-&kappa;B pathway. In this study, a robust in vivo anti-myeloma activity of an IAP antagonist in a transgenic myeloma mouse model and in patients with relapsed-refractory MM was observed, where the addition of cyclophosphamide resulted in a median progression-free-survival of 10 months. Treatment of a MM mouse model with LCL161 established long-term anti-tumor protection and induced regression in a fraction of the mice and, notably, combination of LCL161 with the immune-checkpoint inhibitor anti-PD1 was curative in all of the treated mice.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Peter L. Bergsagel, M.D. - Mayo Clinic Multiple Myeloma SPORE; Project 2: Immunomodulatory Therapy of Multiple Myeloma with SMAC Mimetics; Project Co-Leaders: Martha Chesi, Asher Chanan-Khan</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID:27841872</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>23403992dbd0eb00b86770c08c96191a</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012655 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012655</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>Exposure to mold toxin linked to gallbladder cancer risk</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012655">23807dd2dbd0eb00b86770c08c961992</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:59:24</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>02b23596dbd0eb00b86770c08c961902</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">afb23596dbd0eb00b86770c08c9619a0</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Gallbladder</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Aflatoxin, a poisonous chemical produced by a type of mold often found in corn, is an established risk factor for hepatocellular carcinoma. Although rare in the U.S., aflatoxin exposure is a concern in some areas of the world, including parts of China. Dr. Jill Koshiol and colleagues investigated whether the exposure may also be associated with cancer of the gallbladder, a highly fatal disease. They found an association between a marker of exposure to aflatoxin and gallbladder cancer in a population of men and women in Shanghai, China.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), Shanghai Cancer Institute, Johns Hopkins Bloomberg School of Public Health, University of Copenhagen, Fudan University, M.D. Anderson Cancer Center, Fondap Advanced Center for Chronic Diseases, Stanford University</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28428144</div>
<div>DCEG Research News Highlight: <a href="https://dceg.cancer.gov/news-events/research-news-highlights/2017/aflatoxin-gallbladder-cancer">https://dceg.cancer.gov/news-events/research-news-highlights/2017/aflatoxin-gallbladder-cancer</a>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>4879cad6db14eb00b86770c08c961964</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012687 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012687</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs. peripheral blood unrelated donor transplantation.  Long-term follow up of a randomized trial</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012687">8ab9c21adb14eb00b86770c08c96191b</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:39:53</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>4879cad6db14eb00b86770c08c961964</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">6bb9861adb14eb00b86770c08c9619e6</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Both bone marrow or peripheral blood from unrelated donors may be used for hematopoietic cell transplantation.&nbsp; To understand the better graft source, a randomized Phase 3 multi-center trial to compare the graft sources was conducted in the BMT CTN (BMT CTN 0201), with a primary end point of 2-year survival. This study assessed the quality of life of survivors of patients on this trial at 5 years after transplantation, using mental health well-bearing scores and GVDH symptom scores, and found that both scores were significantly better for bone marrow recipients, and these patients were also more likely to be working full time, suggesting that, although overall survival at 2 years was similar in the primary study analysis, bone marrow should be the standard of care for patients who qualify for allogeneic stem transplantation.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>Lee et al.&nbsp; JAMA Oncology 2016 Dec 2 (12):1583-1589</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Post-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>11b3f196dbd0eb00b86770c08c9619a9</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012657 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012657</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Cancer Research Training Programs</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012657">9e14fd56dbd0eb00b86770c08c961945</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 13:05:25</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>11b3f196dbd0eb00b86770c08c9619a9</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">fe1475d6dbd0eb00b86770c08c9619d3</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>&nbsp;</div>
<div>1. In 2017, CGH sponsored 15 participants from Africa, Asia, Latin America, and the Middle East to the NCI Summer Curriculum held July-August 2017. These participants attended either the NCI Summer Curriculum Principles and Practices of Cancer Prevention and Control course, the Molecular Cancer Prevention course, or both courses. Additionally, CGH nominated 18 participants to attend the NCI Summer Curriculum (CGH did not sponsor these participants) from Africa, Asia, Eastern Europe, the Middle East, and Latin America, and coordinated the participation of 12 participants from the All Ireland Cancer Consortium. CGH's Summer Curriculum International Program is led by Yelena Shnayder.&nbsp;</div>
<div>&nbsp;</div>
<div>2. The Short-Term Scientist Exchange Program (STSEP) promotes collaborative research between researchers at the National Cancer Institute (NCU) and scientists from low, middle, and upper-middle income countries. The program's objective is to facilitate scientific interactions between non-U.S. scientists with researchers at NCI. The STSEP program uses a collaborative funding mechanism. The NCI Center for Global Health (CGH), and the host-Division, Office, or Center within NCI, will defray the cost of the program. In 2017, CGH sponsored 1 STSEP candidate from Cameroon. CGH's STSEP program is led by Vidya Vedham.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CGH</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<div>Office of Cancer Training leads the overall program. For CGH, Yelena Shanyder took the lead.&nbsp; Summer Curriculum Coordinator - Cancer Prevention Fellowship Program</div>
<div>CGH, Vidya Vedham took the lead.</div>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="https://cpfp.cancer.gov/index.php/summer-curriculum">https://cpfp.cancer.gov/index.php/summer-curriculum</a>&nbsp;</div>
<div>Notice for the 2018 Summer Curriculum Application Call: <a href="https://www.cancer.gov/about-nci/organization/cgh/research-training/summer-curriculum-prevention">https://www.cancer.gov/about-nci/organization/cgh/research-training/summer-curriculum-prevention</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Career Development Programs</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>e88ee992dbd0eb00b86770c08c9619cc</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012651 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012651</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>Genome-wide association study identifies multiple risk loci for renal cell carcinoma</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012651">abce2592dbd0eb00b86770c08c961930</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:58:25</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>fb72bd56dbd0eb00b86770c08c9619bd</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">a582fd56dbd0eb00b86770c08c9619ed</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Kidney</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Dr. Mark Purdue, Dr. Kevin Brown, Dr. Nathaniel Rothman, Dr. Stephen Chanock, and colleagues conducted a meta-analysis of six genome-wide association studies of renal cell carcinoma (RCC) including over 10,000 cases and 20,000 controls; they confirmed the six previously known RCC risk loci and identified seven new loci. These findings provide important new leads into the biologic pathways affecting RCC development.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (co-lead), International Agency for Research on Cancer (co-lead), many other collaborators (full list on PubMed: <a href="https://www.ncbi.nlm.nih.gov/pubmed/28598434)">https://www.ncbi.nlm.nih.gov/pubmed/28598434)</a></p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28598434</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>26b0c642db58ab00b86770c08c9619e9</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012632 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012632</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in esophageal squamous cell carcinoma</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012632">8cf04a42db58ab00b86770c08c96193d</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:23:02</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>26b0c642db58ab00b86770c08c9619e9</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">99f00282db58ab00b86770c08c961976</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Esophageal</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Esophageal squamous cell carcinoma (ESSC) is a lethal cancer that is mainly managed with chemotherapy though research has highlighted candidate therapeutic targets such as amplification of the gene encoding the epidermal growth factor receptor (EGFR) tyrosine kinase.&nbsp; NCI supported investigators have recently demonstrated that small-molecule inhibitors are effective in EGFR-amplified ESCC but resistance may quickly develop through reactivation of the mitogen-activated protein kinase pathway.&nbsp; Blockade of this rebound activation with MEK inhibition delays resistance to EGFR monotherapy.&nbsp; The investigators conclude that upfront combination strategies targeting EGFR amplification, guided by adaptive pathway reactivation or by co-occurring genomic alterations, should be considered for clinical testing.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>Nat Commun. 2017 Jan 6;8:13897. doi: 10.1038/ncomms13897</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>78170a56db14eb00b86770c08c96198d</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012680 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012680</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Intravesical rAd-IFNÎ±/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012680">19674696db14eb00b86770c08c96193b</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:29:43</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>78170a56db14eb00b86770c08c96198d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">a2678a96db14eb00b86770c08c9619bd</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Bladder</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>This open-label, multicenter, parallel-arm, Phase II study assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFN&alpha;/Syn3) for patients with high-grade BCG-refractory or relapsed non-muscle invasive bladder cancer. Results showed the of the forty patients that received rAd-IFN&alpha;/Syn3, 35% remained free of high grade recurrence 12 months after initial treatment, and only two of these complete responders experienced recurrence at 21 and 28 months.&nbsp; This study showed that&nbsp; rAd-IFN&alpha;/Syn3 was well tolerated and demonstrated promising efficacy for patients with high-grad non-muscle invasive bladder cancer after BCG therapy who were not able or not willing to undergo radical cystectomy. Based on these results rAd-IFN&alpha;/Syn3 is being advanced to a phase III study.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>The study was supported by FKD Therapies Oy (Finland), the GU SPORE in Bladder Cancer, and by the NCI Cancer Center Support Grant to the MD Anderson Cancer Center.</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="PMID:28834453">PMID:28834453</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>3858318adb18ab00b86770c08c9619fd</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012597 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012597</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Cholesterol metabolite functions as a mediator of the metastatic effects of hypercholesterolemia</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012597">1ab8b58adb18ab00b86770c08c96192e</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:47:09</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>3858318adb18ab00b86770c08c9619fd</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">8cc835cadb18ab00b86770c08c9619f1</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Metastatic</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>&nbsp;</div>
<div>Obesity and elevated circulating cholesterol levels are known risk factors for breast cancer recurrence. Researchers demonstrate that cholesterol mediates the metastatic effects of a high-fat diet via its oxysterol metabolite 27-hydroxycholesterol (27-HC). Inhibiting the enzyme CYP27A1, responsible for the rate-limiting step in 27-HC biosynthesis, significantly reduces metastasis in relevant animal models of cancer. The effect of 27-HC on metastasis requires myeloid immune cell function and it was found to increase polymorphonuclear- neutrophils and gd-T cells at distal metastasis sites. 27-HC functions as a biochemical mediator of the metastatic mediator of hypercholesterolemia.&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://www.nature.com/articles/s41467-017-00910-z.pdf">https://www.nature.com/articles/s41467-017-00910-z.pdf</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>8a643596dbd0eb00b86770c08c961977</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012659 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012659</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Launch of the VHA-NCI Big Data Scientist Training Enhancement Program (BD-STEP)</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012659">ecd47dd6dbd0eb00b86770c08c96193b</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 13:08:34</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>8a643596dbd0eb00b86770c08c961977</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">99d47dd6dbd0eb00b86770c08c96197d</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>The Big Data Scientist Training Enhancement Program (BD-STEP) was collaboratively launched by the Veterans Health Administration and NCI in FY16, embedding graduate student and postdoctoral scientists/engineers in VA medical centers to apply quantitative techniques to challenges in clinical oncology. Twenty fellows have participated since FY16, working together with clinicians on research projects to analyze large-scale patient data sets with the long-term goal of positively impacting patient-centered care. BD-STEP was highlighted as an important program for training the next generation of clinical research scientists in the FY17 NCI Congressional Justification and was cited as an exemplar program for developing the biomedical data scientist workforce in the October 2016 Report of the Cancer Moonshot Task Force. CSSI UPDATE FROM FY16:&nbsp; Recommend keeping for FY17 as program is still active and a new cohort of 15 fellows was launched in October 2017.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CSSI</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>&nbsp;NCI and the Department of Veterans Affairs, Veterans Health Administration (VHA) - VHA is the lead</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<ul style="list-style-position: inside;">
<li>Program website - <a href="https://www.va.gov/oaa/specialfellows/programs/sf_bdstep.asp">https://www.va.gov/oaa/specialfellows/programs/sf_bdstep.asp</a>&nbsp;</li>
<li>Blog from the White House Office of Science and Technology Policy - <a href="https://obamawhitehouse.archives.gov/blog/2015/10/08/increasing-use-data-science-us-department-veterans-affairs-medical-centers">https://obamawhitehouse.archives.gov/blog/2015/10/08/increasing-use-data-science-us-department-veterans-affairs-medical-centers</a>&nbsp;</li>
<li>NCI FY17 CJ (page 30) - <a href="https://www.cancer.gov/about-nci/budget/congressional-justification/fy2017-nci-congressional-justification.pdf">https://www.cancer.gov/about-nci/budget/congressional-justification/fy2017-nci-congressional-justification.pdf</a>&nbsp;</li>
<li>Cancer Moonshot Taskforce Report (page 24) - <a href="https://obamawhitehouse.archives.gov/sites/default/files/docs/final_cancer_moonshot_task_force_report_1.pdf">https://obamawhitehouse.archives.gov/sites/default/files/docs/final_cancer_moonshot_task_force_report_1.pdf</a></li>
</ul>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Career Development Programs</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>ecc18292db14eb00b86770c08c9619f2</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012667 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012667</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</revised_by>
<roles/>
<short_description>Conversion of "Cold" Tumors into "Hot" Tumors by Combining Immunotherapies</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012667">b512c292db14eb00b86770c08c961943</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:08:01</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>d362c292db14eb00b86770c08c961926</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">f0820e92db14eb00b86770c08c961910</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Melanoma</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Ribas et al. reported results from a Phase Ib trial in which synergistic effects of combining intratumoral injection of oncolytic virus talimogene laherparepvec and intravenous anti-PD-1 antibody pembrolizumab were observed in advanced melanoma with low or no pre-treatment CD8+ tumor-infiltrating lymphocytes (&ldquo;cold&rdquo; tumor). Following administration of virus, recruitment of CD8+ T cells into the tumor microenvironment (&ldquo;hot&rdquo; tumor) and increased expression of PD-L1 on tumor cells were observed in patients who responded to this combination therapy. With an objective response rate of 62% and a complete response rate of 33% confirmed from this trial, a randomized Phase III trial was opened.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>Reference: Ribas A et al., "Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy" Cell (2017) 170:1109-1119; Grant R35CA197633 (PI: Ribas, Antoni) &ldquo;Immuno-Targeted Therapy for Melanoma&rdquo;</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>94308212db14eb00b86770c08c96193d</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012663 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012663</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Interim results from the CATNON trial (EORTC study 26053-22054 RTOG 0834) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomized, open-label intergroup study [SMR: Publication date 10/07/17 â FY18]</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012663">7e704a12db14eb00b86770c08c9619cd</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 13:59:31</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>94308212db14eb00b86770c08c96193d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">44800652db14eb00b86770c08c9619de</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Brain</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The study showed survival benefit from adjuvant chemotherapy with temozolomide in a subset of patients with anaplastic glioma characterized by a molecular marker.&nbsp; At the time of the interim analysis, 745 (99%) of the planned 748 patients had been enrolled. The hazard ratio for overall survival with use of adjuvant temozolomide was 0&middot;65 (99&middot;145% CI 0&middot;45-0&middot;93). Overall survival at 5 years was 55&middot;9% (95% CI 47&middot;2-63&middot;8) with and 44&middot;1% (36&middot;3-51&middot;6) without adjuvant temozolomide. Grade 3-4 adverse events were seen in 8-12% of 549 patients assigned temozolomide, and were mainly hematological and reversible.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>This was a collaboration between the National Cancer Institute NCTN Group (RTOG) and the EORTC.&nbsp; RTOG joined this international trial that was led by the EORTC</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28801186</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>ef4da952dbd0eb00b86770c08c9619a8</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012648 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012648</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>Increased risk of cancer after pediatric organ transplantation</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012648">8cbd6152dbd0eb00b86770c08c961934</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:52:13</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>4d117916dbd0eb00b86770c08c9619b0</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">ae113d16dbd0eb00b86770c08c96192c</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Pediatric, Rare</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Organ transplant recipients must utilize immunosuppressive medications to prevent rejection of the transplanted organ, resulting in weakened immune systems over their life span. The spectrum of cancer risk in pediatric transplant recipients may differ from that in adults, because their immune system is still developing, and often children have not yet been exposed to some cancer-causing viruses. A new analysis led by Dr. Eric Engels and former DCEG fellow Dr. Elizabeth Yanik shows a considerable increase in risk for several cancers following organ transplantation in childhood, especially for non-Hodgkin lymphoma (manifesting more than 200-fold increase in risk) which is often caused by Epstein-Barr virus. Investigators conducted the study using data from nearly 18,000 pediatric transplant recipients in the Transplant Cancer Match Study, making this the largest study of cancer in the pediatric transplant population to date.&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), University of Washington, Cancer Prevention Institute of California, University of Iowa, New York State Cancer Registry, Illinois State Cancer Registry, New Jersey State Cancer Registry</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28557749</div>
<div>DCEG Research News Highlight: <a href="https://dceg.cancer.gov/news-events/research-news-highlights/2017/pediatric-transplant">https://dceg.cancer.gov/news-events/research-news-highlights/2017/pediatric-transplant</a>&nbsp;</div>
<div>Transplant Cancer Match Study: <a href="https://transplantmatch.cancer.gov/">https://transplantmatch.cancer.gov/</a>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>17514652db14eb00b86770c08c961938</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012666 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012666</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>GOG-249 Confirms Adjuvant Pelvic Radiation as Standard of Care for High-Risk, Early-Stage Endometrial Cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012666">a6b14652db14eb00b86770c08c961952</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:04:58</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>17514652db14eb00b86770c08c961938</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">f3b1c292db14eb00b86770c08c96193f</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Endometrial</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology (GOG-249) presented at the American Society for Radiation Oncology (ASTRO) 2017, recurrence-free and overall survival rates for women with stage I-II high-risk endometrial cancer were not superior following vaginal cuff brachytherapy plus chemotherapy when compared with pelvic radiation therapy.&nbsp; There were no statistically significant increases in recurrence-free survival (RFS) or overall survival (OS) in the brachytherapy-chemotherapy arm. At a median follow-up of 53 months, 82 percent of patients were alive and recurrence free at three years for both the adjuvant external beam RT to the pelvis (PXRT) or vaginal cuff brachytherapy plus chemotherapy (VCB/C) patient groups. Three-year OS rates were 91 percent for pelvic radiation and 88 percent for the brachytherapy-chemotherapy combination, but this difference was not statistically significant (p = 0.57).&nbsp; Risks of pelvic and para-aortic nodal recurrence and frequency of short-term side effects were greater for the brachytherapy-chemotherapy approach. High completion rates for each treatment arm suggest that both therapies are well-tolerated by patients.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="https://www.astro.org/uploadedFiles/_MAIN_SITE/News_and_Publications/News_and_Media_Center/News_Releases/2017/ASTRO17_Randall.pdf">https://www.astro.org/uploadedFiles/_MAIN_SITE/News_and_Publications/News_and_Media_Center/News_Releases/2017/ASTRO17_Randall.pdf</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>8c704242db58ab00b86770c08c9619fb</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012631 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012631</number>
<published>2018-09-06</published>
<rating/>
<retired/>
<revised_by display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</revised_by>
<roles/>
<short_description>Direct detection of early-stage cancers using circulating tumor DNA</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012631">2ea04e42db58ab00b86770c08c961925</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-06 15:47:08</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>224ce007db9c2f0054d8ff621f96199d</sys_id>
<sys_mod_count>5</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">658cac47db9c2f0054d8ff621f96197f</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The detection and analysis of circulating tumor DNA from cancer patients was not feasible for early diagnosis because of insufficient amount of DNA in the blood samples.&nbsp; Dr. Victor Velculescu and colleagues from the Johns Hopkins University have recently developed a novel method called targeted error correction sequencing which significantly increases the sensitivity of mutation detection from early-stage cancer patients.&nbsp; Using this method, the team screened the blood samples for mutations within 58 known cancer-related genes. They detected no tumor-derived mutations in the blood samples from the healthy people. However, in the samples from patients with colorectal, breast, lung, or ovarian cancer, the technique identified tumor-related DNA mutations in 48 of 62 patients (77%) with advanced cancer (stages III and IV) and in 86 of 138 patients (62%) with stage I or stage II cancer. This result suggests that early detection of cancer by sequencing circulating tumor DNA is a feasible approach.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="http://stm.sciencemag.org/content/9/403/eaan2415.full">http://stm.sciencemag.org/content/9/403/eaan2415.full</a>&nbsp;</div>
<div><a href="https://www.nih.gov/news-events/nih-research-matters/detecting-early-signs-cancer-blood">https://www.nih.gov/news-events/nih-research-matters/detecting-early-signs-cancer-blood</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>2dafe992dbd0eb00b86770c08c961956</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012653 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012653</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>Common inherited variant influences breast cancer risk after chest radiotherapy for survivors of childhood cancerÂ  [SMR: Publication Date 11/2017; also added to FY18 worksheet]</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012653">e0007dd2dbd0eb00b86770c08c961926</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:58:58</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>b7927196dbd0eb00b86770c08c9619ac</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">dda2b196dbd0eb00b86770c08c9619f9</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Breast, Pediatric</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Childhood cancer survivors, particularly those who received radiation to the chest as part of their treatment, are known to be at elevated risk of developing breast cancer later in life. Led by Dr. Lindsay Morton, investigators conducted a genome-wide association study of nearly 3,000 female survivors of childhood cancer to identify whether inherited genetic susceptibility may influence which survivors go on to develop breast cancer. Using data from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort, researchers pinpointed a single-nucleotide polymorphism (SNP) on chromosome 1q41 that increased breast cancer risk about two-fold per copy of the risk allele among patients treated with radiation to the chest. The variant did not appear to affect risk among survivors who did not receive chest radiotherapy.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center, University of Chicago, Nationwide Children's Hospital and the Ohio State University School of Medicine, University of Minnesota, Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, Cincinnati Children's Hospital Medical Center, University of Alabama at Birmingham</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 29059430</div>
<div>DCEG Research News Highlight: <a href="https://dceg.cancer.gov/news-events/research-news-highlights/2017/childhood-survivors-breast-gwas">https://dceg.cancer.gov/news-events/research-news-highlights/2017/childhood-survivors-breast-gwas</a>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>f22e6d52dbd0eb00b86770c08c9619ca</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012650 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012650</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>In-depth investigation of genetic region identifies mechanism that contributes to cancer susceptibility</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012650">427e6d52dbd0eb00b86770c08c9619b2</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:58:12</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>2c723556dbd0eb00b86770c08c9619ec</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">9e72bd56dbd0eb00b86770c08c9619ba</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Dr. Laufey Amundadottir, Dr. Kevin Brown, and colleagues have identified a functional genetic variant in a multi-cancer risk locus at chromosome 5p15.33 that explains, at least in part, the molecular mechanism through which this locus influences risk of multiple cancer types. Genome-wide association studies (GWAS) have previously revealed up to seven independent cancer susceptibility loci in this genomic region that includes the TERT and CLPTM1L genes. Specifically, variants at one of these loci over the CLPTM1L gene increase risk of pancreatic cancer and testicular cancer, while decreasing risk of lung cancer and melanoma. This study found that the functional variant influences TERT expression, and potentially telomere length, through its effects on a distant gene regulatory element with a molecular mechanism common to all four cancers regardless of the direction of effect on cancer risk.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<div>NCI (lead), University of Arkansas for Medical Sciences, University of Maryland School of Public Health, University of California at San Francisco, University of Maryland School of Medicine, Vanderbilt-Ingram Cancer Center, Frederick National Laboratory for Cancer Research</div>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28447668</div>
<div>Research News Highlight: <a href="https://dceg.cancer.gov/news-events/research-news-highlights/2017/tert-regulation">https://dceg.cancer.gov/news-events/research-news-highlights/2017/tert-regulation</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>c02f3512db14eb00b86770c08c96198e</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012660 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012660</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321)</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012660">e57fb112db14eb00b86770c08c961964</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 13:55:03</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>c02f3512db14eb00b86770c08c96198e</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">bf7fb912db14eb00b86770c08c961942</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Rare, Pediatric, Metastatic</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>This is the first prospective, multi-institutional, international study to show that intensive multi-modality therapy is highly effective for patients with a rare tumor type - i.e., regional extra-ocular retinoblastoma (RB) and metastatic RB not involving the central nervous system (CNS).&nbsp; Event-free survival (EFS) at 36 months was 87.7% (90% CI 65.4 to 96.0%) for subjects with stage 2 or 3 disease, 79.3% (90% CI 54.2 to 91.6%) for subjects with stage 4a disease, and 8.0% (90% CI 1.0 to 25.1%) for subjects with stage 4b/trilateral disease.&nbsp; The observed results significantly improved the EFS in each stratum compared with historical results used for planning the study.&nbsp; More effective therapy is required for patients with CNS RB.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>Dunkel IJ, Krailo MD, Chantada GL et al. Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321).&nbsp; J Clin Oncol 35, 2017 (suppl; abstr 10506).</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>3d55710adb18ab00b86770c08c96197e</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012590 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012590</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Identification of a new route for the phospho-inhibition of Ras pathway signaling</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012590">28267dc6db18ab00b86770c08c961954</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:35:49</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>3d55710adb18ab00b86770c08c96197e</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">7526b54adb18ab00b86770c08c961928</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>More than one-third of all human cancers carry defects in a gene called Ras. In such cancers, the gene produces a dysfunctional form of the Ras protein, which normally acts as an on/off switch in a cellular growth pathway called the Ras pathway. The dysfunctional Ras protein gets stuck in the &ldquo;on&rdquo; state, resulting in uncontrolled cell growth and tumor formation. CCR researcher Debbie Morrsion reported the discovery of a previously unknown route for blocking cell growth that can be activated by certain chemotherapy drugs to fight cancer. This advance suggests that chemotherapy drugs targeting communication between the stress-response and Ras pathways may offer a novel treatment approach for the large number of human tumors carrying Ras mutations, including pancreatic cancers of which 95% contain such mutations. Given the few drugs available to treat these cancers, finding novel ways to target Ras-mutant cancers is an important first step toward discovering new cures.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc/>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 27889448</div>
<div><a href="https://ccr.cancer.gov/news/article/chemotherapy-drug-shuts-down-cell-growth-by-triggering-a-natural-checkpoint">https://ccr.cancer.gov/news/article/chemotherapy-drug-shuts-down-cell-growth-by-triggering-a-natural-checkpoint</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>8fed758edb18ab00b86770c08c961912</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012618 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012618</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012618">a63e79cedb18ab00b86770c08c9619ee</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:11:12</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>8fed758edb18ab00b86770c08c961912</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">084e7dcedb18ab00b86770c08c9619b3</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Melanoma</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>This study highlights the microenvironmental factors involved in mechanisms related to resistance to melanoma treatments. Klotho is a serum factor which decreases with age and plays a role in the aged microenvironment. Mouse studies with PPAR gamma inhibitor rosglitizone, show increased expression of klotho and decreases in Wnt5A in tumor cells and decreases tumors in both BRAF inhibitor&ndash;sensitive and BRAF inhibitor&ndash;resistant aged mice Glitazone drugs may be used as adjuvant therapy for older melanoma patients who have developed resistance to vemurafenib.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Wistar U/Penn Skin SPORE (Supporting Grants: P50CA174523); Ashani Weeraratna</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28232477</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>4944c216db14eb00b86770c08c961912</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012671 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012671</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Cellular immunotherapy targets a common human cancer mutation</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012671">178402d2db14eb00b86770c08c961967</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:17:18</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>4944c216db14eb00b86770c08c961912</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">8d948616db14eb00b86770c08c9619ec</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Colon/colorectal</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>In a study of an immune therapy for colorectal cancer that involved a single patient, a team of researchers in CCR identified a method for targeting the cancer-causing protein produced by a mutant form of the KRAS gene. This targeted immunotherapy led to cancer regression in the patient in the study. This this work demonstrates for the first time a proof-of-principle method which will need additional study.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 27959684</div>
<div><a href="https://www.nih.gov/news-events/news-releases/cellular-immunotherapy-targets-common-human-cancer-mutation">https://www.nih.gov/news-events/news-releases/cellular-immunotherapy-targets-common-human-cancer-mutation</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>e2ed3906db18ab0054d8ff621f961970</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012617 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012617</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Intestinal Microbiota and relapse after hematopoietic-cell transplantation</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012617">132e7146db18ab0054d8ff621f961996</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:10:58</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>e2ed3906db18ab0054d8ff621f961970</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">372e3546db18ab0054d8ff621f96192b</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Intestinal bacteria have been shown to be potent modulators of the immune response, and in fact alterations in the intestinal flora appears be associated with overall survival after allogeneic hematopoietic cell transplant (allo-HCT).&nbsp; Although associations between intestinal flora and mortality caused by graft-vs-host disease has been demonstrated, this study now examines association of microbiota species and risk of relapse/progression post-HCT.&nbsp; The findings show stool samples that contained a high abundance of a bacterial group composed mostly of Eubacterium limosum were associated with less relapse at 2 years than those patients without this particular group of bacteria, and these associations remained significant in multivariate&nbsp; &nbsp;models were strongest among recipients that were T-cell replete.&nbsp; The results suggest that microbiome might serve as biomarkers for relapse and microbiota alteration might serve as a new therapeutic modality post-HCT relapse.&nbsp;&nbsp;</div>
<div>&nbsp;</div>
<div>c) Provide relevant PMIDs, program websites, or web links to Press Releases:&nbsp;</div>
<div>&nbsp;</div>
<div>d) Indicate the ICOs/ agencies/ organizations involved if citing a collaboration, including who was the lead:</div>
<div>&nbsp;</div>
<div>e) DOC:&nbsp;</div>
<div>&nbsp;</div>
<div>f) Cancer Type:</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28296583</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>146342d2db14eb00b86770c08c9619a3</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012669 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012669</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012669">a0a34ad2db14eb00b86770c08c9619de</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:13:17</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>146342d2db14eb00b86770c08c9619a3</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">f9a34ed2db14eb00b86770c08c961941</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Leukemia</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Although ibrutinib is FDA approved for first line treatment for chronic lymphocytic leukemia (CLL), and the overall response rate ibrutinib is high, the complete response (CR) rate is low, and survival of patients who experienced progression while receiving ibrutinib is short, with one study reporting median overall survival (OS) of only 3 months.&nbsp; This study has examined the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T cell therapy in patients who have previously received ibrutinib.&nbsp; Of 24 patients who received the drug, 19 experienced progression 3 were ibrutinib intolerant and 3 did not progress.&nbsp; Of these patients, the overall response rate (CR or PR) was 71%, with 7 of 12 patients who had deep IGH sequencing had no malignant IGH sequences in their marrow.&nbsp; Thus, CD19 CAR-T cells is highly effective in high risk patients with CLL who experience treatment failure with ibrutinib therapy.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28715249</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>55324682db58ab00b86770c08c961932</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012642 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012642</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Identification of Druggable Targets in Non-Small Cell Lung Cancer (NSCLC)</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012642">d182ca82db58ab00b86770c08c961959</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:29:57</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>55324682db58ab00b86770c08c961932</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">4782c2c2db58ab00b86770c08c96193f</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Lung</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Lung cancer is the leading cause of death in the United States, and non-small cell lung cancer (NSCLC) accounts for 85%-90% of lung cancers which display resistance to chemotherapy. CTD2 investigators identified XPO1, a nuclear export receptor as an essential gene for survival in KRAS mutant NSCLC. This preclinical study has provided supporting evidence for the initiation of a phase 1/2 clinical trial.&nbsp;</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>This work was supported by funds from the National Cancer Institute / Office of Cancer Genomics and the Cancer Prevention Research Institute of Texas(CPRIT)</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 27680702</div>
<div><a href="https://clinicaltrials.gov/ct2/show/NCT03095612">https://clinicaltrials.gov/ct2/show/NCT03095612</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>a1948616db14eb00b86770c08c961920</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012672 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012672</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>CCR's role in Avelumab FDA approval</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012672">51d406d2db14eb00b86770c08c9619cf</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:18:32</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>a1948616db14eb00b86770c08c961920</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">17d44a16db14eb00b86770c08c9619f5</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Skin, Rare, Metastatic</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The U.S. Food and Drug Administration on March 23, 2017 approved the immunotherapy drug avelumab for metastatic Merkel cell carcinoma (MCC) &mdash; a rare, aggressive form of skin cancer &mdash; for adults and patients 12 years of age and older. Avelumab, marketed as Bavencio, is the first FDA-approved treatment for MCC. Trials based at the Center for Cancer Research (CCR), whose infrastructure allows unparalleled, seamless collaboration between basic and clinical researchers, were instrumental in streamlining avelumab&rsquo;s approval.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR, Rutgers Cancer Institute of New Jersey, Pfizer, Merck, EMD Serono Inc</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMIDs: 27592805, 28373005&nbsp;</div>
<div><a href="https://ccr.cancer.gov/news/article/ccr-plays-key-role-in-first-FDA-approved-drug-for-treatment-of-merkel-cell-carcinoma">https://ccr.cancer.gov/news/article/ccr-plays-key-role-in-first-FDA-approved-drug-for-treatment-of-merkel-cell-carcinoma</a></div>
<div><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2017/avelumab-fda-merkel-cell">https://www.cancer.gov/news-events/cancer-currents-blog/2017/avelumab-fda-merkel-cell</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>ad37718adb18ab00b86770c08c96199a</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012594 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012594</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Lineage plasticity and antiandrogen resistance in TP53 -and RB1-deficient prostate cancer</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012594">2f77754adb18ab00b86770c08c9619cf</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:41:46</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>ad37718adb18ab00b86770c08c96199a</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">6087b58adb18ab00b86770c08c96199c</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Prostate</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Drugs that target the Androgen Receptor (AR), such as enzalutamide, are initially effective in the treatment of prostate cancer, but most tumors will eventually develop resistance. Studies from Charles Sawyers, David Goodrich, and Leigh Ellis demonstrate prostate cancer resistance to drugs that target AR via a switch from AR-dependent luminal cells to AR-independent neuroendocrine cells. The studies found that prostate cancer lineage plasticity enabled by loss of the tumor suppressors TP53 and RB1 involved increased expression of the epigenetic factors, Sox2 and Ezh2, that drive a newly identified mechanism of resistance involving rapid transcriptional reprogramming/phenotype switching.&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMIDs: 28058767, 28059768</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>1babe912dbd0eb00b86770c08c961975</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012644 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012644</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>International consortium adds 72 genetic variants to list of known breast cancer associations [SMR: Publication date is 10/23/17 (FY18)]</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012644">131c2152dbd0eb00b86770c08c961998</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:51:23</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>78e07dd2dbd0eb00b86770c08c961947</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">6ae07916dbd0eb00b86770c08c961944</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Breast</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>DCCPS-funded OncoArray Network researchers from 300 institutions around the world combined forces to discover 72 previously unknown gene mutations that lead to the development of breast cancer. The teams found that 65 of the newly identified genetic variants are common among women with breast cancer. The remaining seven mutations predispose women to developing a type of breast cancer known as estrogen-receptor-negative breast cancer, which doesn't respond to hormonal therapies, such as the drug tamoxifen. The new discoveries add to previous research bringing the total number of known variants associated with breast cancer to nearly 180.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCCPS</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>&nbsp;Dr. Stephen Chanock of the Division of Cancer Epidemiology and Genetics (DCEG) coauthored the study</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div><a href="http://www.nature.com/nature/journal/vaop/ncurrent/full/nature24284.html">http://www.nature.com/nature/journal/vaop/ncurrent/full/nature24284.html</a> <a href="https://www.nature.com/articles/ng.3785">https://www.nature.com/articles/ng.3785</a></div>
<div><a href="https://epi.grants.cancer.gov/oncoarray/;">https://epi.grants.cancer.gov/oncoarray/;</a> <a href="https://dceg.cancer.gov/news-events/research-news-highlights/2017/breast-cancer-oncoarray">https://dceg.cancer.gov/news-events/research-news-highlights/2017/breast-cancer-oncoarray</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>391d758edb18ab00b86770c08c961961</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012613 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012613</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>CDK4/6 inhibition triggers anti-tumor immunity</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012613">157db1cedb18ab00b86770c08c9619d4</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:07:50</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>391d758edb18ab00b86770c08c961961</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">c37df1cedb18ab00b86770c08c9619a1</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Breast</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Drivers of the cell cycle typically are involved in the initiation and progression of various malignancies and thus, ideal targets for therapy.&nbsp; In particular, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors can induce cell cycle arrest in tumor cells.&nbsp; In this study, researchers identify the molecular mechanisms of action involved in preclinical mouse models and confirm this phenomenon through biopsies of breast cancer patients treated with CDK4/6 inhibitor.&nbsp; Their results show that CDK4/6 inhibitors increase tumor immunogenicity and provide a rationale for new combination regimens comprising CDK4/6 inhibitors and immunotherapies as anti-cancer treatment.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Dana-Farber Harvard Cancer Institute Breast SPORE P50CA168504</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28813415</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>d4d88a96db14eb00b86770c08c961981</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012685 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012685</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Continued Support and Development of NCI-MATCHBox system to support NCI-MATCH and Pediatric MATCH</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012685">e829cad6db14eb00b86770c08c96193d</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:37:20</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>d4d88a96db14eb00b86770c08c961981</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">4e29ced6db14eb00b86770c08c961987</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Pediatric, Rare</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>MATCHBox is an expert system which provides automated research patient workflow management and automated algorithm-driven treatment assignment based on gene mutation, disease and patient characteristics. The MATCHBox team responsibilities include software requirement analysis, design, development, documentation, testing informatics and data components, automated software deployment, data storage, and analytics. The system is fully-integrated with the MATCH sequencing laboratory network and clinical data management systems to support oncologists, pathologists, geneticists, sequencing laboratory personnel, clinical research staff, and the executive leadership from five organizations including NCI. As NCI-MATCH evolves over time so does MATCHBox, with a continuous innovation methodology. MATCH has completed the screening of 6300+ patients. NCI is currently supporting the designated lab referral program. For Pediatric MATCH, which was launched July 24, CBIIT provides all the same capabilities with the additional responsibility of configuring the sequencing pipeline.&nbsp; Pediatric MATCH includes the implementation of the first-of-its-kind cloud infrastructure and hosted application.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CBIIT</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI/CBIIT (David Patton); FNLCR DSITP (Brent Coffey); NCI/DCTD/CDP (Barb Conley/Lyndsay Harris); ECOG-ACRIN (Peter O'Dwyer); FNLCR MoCha (Mickey Williams); MD Anderson (Stan Hamilton); Yale (Jeff Sklar); MGH (John Iafratre); Dartmouth (Francine Blumental de Abreu); Nationwide Children's Hospital (Julie Gastier-Foster); COG (Peter Adamson)</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>MATCHBox is a non-public facing system. It has been cited in various presentations and the recent NCI-MATCH Assay paper in the Journal of Molecuar Diagnostics. A manuscript is currently in development. <a href="https://www.cancer.gov/news-events/press-releases/2017/nci-pediatric-match-trial-opens">https://www.cancer.gov/news-events/press-releases/2017/nci-pediatric-match-trial-opens</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>da747dc6db18ab00b86770c08c961903</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012588 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012588</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Insights into the pre-metastatic niche formation and metastasis</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012588">61c4bdc6db18ab00b86770c08c9619ea</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:29:53</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>da747dc6db18ab00b86770c08c961903</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">76c4b50adb18ab00b86770c08c96199a</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Metastatic</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Perivascular cells are a small population of cells that sit in between blood vessel walls and the surrounding tissue. They are important for sensing stress or injury around blood vessels and giving instructions to other cells to help repair the injury. CCR investigator, Rosie Kaplan, found that a gene called Klf4 causes a phenotype switch in perivascular cells in mice that promotes metastasis of melanoma, breast cancer, and pediatric rhabdomyosarcoma tumors. Specifically, these signals prompt perivascular cells to grow faster, become more mobile, and produce proteins that help tumor cells settle in and grow. Understanding these processes may lead to way to limit metastasis.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28920957</div>
<div><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2017/metastatic-cancer-kaplan">https://www.cancer.gov/news-events/cancer-currents-blog/2017/metastatic-cancer-kaplan</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>0e3e3546db18ab0054d8ff621f96195b</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012619 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012619</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Genomic Data Commons (GDC) Data Analysis, Visualization and Exploration (DAVE) Tools</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012619">836e7146db18ab0054d8ff621f961989</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:12:03</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>0e3e3546db18ab0054d8ff621f96195b</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">bb6eb546db18ab0054d8ff621f9619c3</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>DAVE is a new web interface for exploring and analyzing cancer genomic data, in real time, online, without the need to download or process the data. DAVE helps the GDC fulfill its mission of making research data widely accessible and usable by bringing the information technology infrastructure required for downloading, storing, and analyzing big data directly to researchers, making it easy for anyone in the cancer research community to work with the data available in the GDC. Researchers can navigate from project cohorts to individual patients, to specific genes and mutations of interest. DAVE includes specialized graphs to help researchers visualize genomic &ldquo;signatures&rdquo; of cancer and identify potential drivers of disease. Users can also plot patient survival curves and identify the molecular consequence of a mutation on the resultant protein.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>DAVE page on the GDC website:&nbsp; <a href="https://gdc.cancer.gov/analyze-data/gdc-dave-tools;">https://gdc.cancer.gov/analyze-data/gdc-dave-tools;</a> Cancer Currents blog post about DAVE:&nbsp; <a href="https://gdc.cancer.gov/analyze-data/gdc-dave-tools;">https://gdc.cancer.gov/analyze-data/gdc-dave-tools;</a> CCG blog post about DAVE tools:&nbsp; <a href="https://www.cancer.gov/about-nci/organization/ccg/blog/2017/gdc-dave-tour">https://www.cancer.gov/about-nci/organization/ccg/blog/2017/gdc-dave-tour</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>59258a16db14eb00b86770c08c961934</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012674 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012674</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>CAR T-Cell therapy can lead to long-lasting remissions in patients with lymphoma</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012674">a1654256db14eb00b86770c08c961928</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:21:00</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>59258a16db14eb00b86770c08c961934</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">ea654256db14eb00b86770c08c96198f</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Lymphoma</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Chimeric antigen receptor (CAR) T-cell therapy is an experimental cancer treatment in which patients&rsquo; immune cells are reprogrammed to fight their disease. In clinical trials, the treatment has been very effective for some patients with the aggressive blood cancer diffuse large B-cell lymphoma (DLBCL). After the longest follow-up to date of patients who received CAR T-cell therapy, CCR scientists are now reporting that the remissions induced by the treatment can be long lasting. The results suggest that CAR T cells may be curative for diffuse large B cell lymphoma patients.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28803861</div>
<div><a href="https://ccr.cancer.gov/news/article/car-t-cell-therapy-can-lead-to-long-lasting-remissions-in-patients-with-lymphoma">https://ccr.cancer.gov/news/article/car-t-cell-therapy-can-lead-to-long-lasting-remissions-in-patients-with-lymphoma</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>a9114e42db58ab00b86770c08c96198f</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012634 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012634</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Development of the Applied Proteogenomics OrganizationaL Learning and Outcomesâ Network (APOLLO)</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012634">e9410282db58ab00b86770c08c961921</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:24:30</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>a9114e42db58ab00b86770c08c96198f</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:24</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">cb414682db58ab00b86770c08c96190b</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>APOLLO is a tri-agency consortium of the Department of Defense (DoD), Department of Veterans Affairs (VA), and the National Cancer Institute (NCI) using the emerging field of proteogenomics to better detect cancer and to apply targeted therapies based on the unique characteristics of each individual&rsquo;s tumor. APOLLO brings together the NCI with the nation's two largest health care systems, the DoD and VA, to screen patients with lung cancer for genomic abnormalities and proteomic information that can be used to match their tumor types to targeted cancer therapies.&nbsp; APOLLO is a program developed through the Beau Biden Cancer Moonshot Initiative.&nbsp; &nbsp;Launched in 2016, the APOLLO program creates the nation's first fully integrated, discovery-to-implementation system for proteogenomic oncology, with plans to expand the program to involve other U.S. and global health care systems.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CSSI</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI, DoD, VA</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>White House Fact Sheet: <a href="https://obamawhitehouse.archives.gov/the-press-office/2016/06/28/fact-sheet-cancer-moonshot-summit-vice-president-biden-announces-new">https://obamawhitehouse.archives.gov/the-press-office/2016/06/28/fact-sheet-cancer-moonshot-summit-vice-president-biden-announces-new</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Pre-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>e9cd6152dbd0eb00b86770c08c961936</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012649 v2.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012649</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</revised_by>
<roles/>
<short_description>Association of estrogen metabolism with breast cancer risk in different cohorts of postmenopausal women</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012649">bf1ea912dbd0eb00b86770c08c961975</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 12:57:48</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>36523d56dbd0eb00b86770c08c9619bc</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="2.0">50627d56dbd0eb00b86770c08c961953</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Breast</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Prospective epidemiologic studies have consistently linked elevated circulating estradiol and estrone to increased postmenopausal breast cancer risk. Dr. Joshua Sampson, Dr. Gretchen Gierach, and colleagues evaluated multiple competing hypotheses for how metabolism of these parent estrogens may influence breast cancer risk by using a highly sensitive and reliable liquid chromatography with tandem mass spectrometry assay developed in collaboration with NCI-Frederick to evaluate prediagnostic concentrations of estrogen analytes in four cohorts of postmenopausal women. They demonstrated that relative increases in levels of 16-hydroxylation pathway metabolites, as compared to 2-hydroxylation metabolites, are significantly associated with increased breast cancer risk after adjusting for total estrogen levels. With appropriate validation, these findings suggest opportunities for breast cancer prevention by modifying individual estrogen metabolism profiles through either lifestyle alterations or chemopreventive strategies.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCEG</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (lead), University of Arkansas for Medical Sciences, University of Maryland School of Public Health, University of California at San Francisco, University of Maryland School of Medicine, Vanderbilt-Ingram Cancer Center, Frederick National Laboratory for Cancer Research</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28011624</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Epidemiological</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>438d3d06db18ab0054d8ff621f96194a</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012615 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012615</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>An early-biomarker algorithm predicts lethal graft-versus-host disease and survival</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012615">b2cdf506db18ab0054d8ff621f9619f1</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:09:18</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>438d3d06db18ab0054d8ff621f96194a</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">2fcdfd06db18ab0054d8ff621f96198c</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>No laboratory test is currently available to predict the risk of severe acute graft-vs-host disease (aGVHD) leading to non-relapse mortality (NRM) after hematopoietic stem cell transplantation (HCT) prior to the onset of GHVD symptoms.&nbsp; This study, testing blood samples only 7 days after HCT, posits a 2-biomarker model (ST2 and REG3 concentrations) identified patients with a cumulative incidence of 6-month NRM in the high-risk group vs. 7% in the low-risk group, with GVHD-related mortality of 18% in high-risk vs. 4% in low risk groups, and the same algorithm can be applied to define 3 risk groups at aGVHD onset.&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28194439</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>8f9a3d82db18ab0054d8ff621f96194f</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012602 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012602</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Building a program in extramural funding for Global Cancer Research: Affordable Cancer Technologies Program</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012602">e1da3d82db18ab0054d8ff621f961915</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:56:23</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>8f9a3d82db18ab0054d8ff621f96194f</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">23dafd82db18ab0054d8ff621f9619e2</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Affordable Cancer Technologies Program: CGH works with other NCI divisions, the SBIR program, and other offices and centers to support the development and validation of affordable, portable technologies with the potential to increase early detection, diagnosis, and non-invasive or minimally invasive treatment of cancer. In FY2017, CGH supported the addition of a third cohort of investigator teams for the Act program (7 grants). Additionally, 6 grants from the first cohort of investigator teams successfully transition from the validation phase to the build phase of their projects in FY17. There is a total of 20 active projects in this program. There is also a forthcoming SBIR/STTR program that has SPL approval and is the product of a collaboration between CGH and SBIR DC (SBIR is the lead).</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CGH</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI (in collaboration with CRCHD, SBIR, OHAM, DCP, DCTD, DCCPS) and NIBIB. NCI took the lead, for CGH, Paul Pearlman took the lead.&nbsp;</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references/>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>4f67ce56db14eb00b86770c08c9619aa</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012681 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012681</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012681">cca78296db14eb00b86770c08c961991</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:30:44</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>4f67ce56db14eb00b86770c08c9619aa</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">beb74e96db14eb00b86770c08c9619e5</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Bladder</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>This study confirmed that overexpression of Aurora kinase A (AURKA) and activation of its downstream pathway was enriched in the basal subtype of primary human bladder cancer, a highly aggressive subtype of the disease.&nbsp; Whole genome mRNA expression profiling identified nicotinamide N-methyltransferase (NNMT) as a downstream target of AURKA, attenuating NNMT blockage of tumor cell invasion in vitro.&nbsp; The study also showed that the FISH test for the AURKA gene copy number in urine yielded a specificity and sensitivity with an AUC of 0.901, a high level of test performance which implicates AURKA as an effective biomarker for bladder cancer for non-invasive detection and monitoring, as well as a potential therapeutic target, especially for the basal subtype of bladder cancer.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>This study was supported in part by grants from NIH R01CA151489 and P50 CA91846 (Project 1 and Core C).</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p><a href="PMID:28102366">PMID:28102366</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>1c8f3112db14eb00b86770c08c961907</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012661 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012661</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>A Phase 3 Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine vs Saline in Pts with Newly Diagnosed or Occasionally Recurring Grade I/II Non-Muscle Invasive Bladder Cancer:  SWOG S0337</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012661">fcdf7d12db14eb00b86770c08c961953</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 13:56:39</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>1c8f3112db14eb00b86770c08c961907</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">75df7d12db14eb00b86770c08c9619d2</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Bladder</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>The study showed that risk of bladder cancer recurrence after treatment could be reduced by administration of chemotherapy into the bladder after surgery. Immediate, instillation of the common chemotherapy agent gemcitabine after removal of a newly diagnosed or occasionally recurring Grade I, II, superficial bladder cancer significantly reduces the risk of cancer recurrence.&nbsp; The S0337 trial showed a 34% reduction in risk of recurrence in patients receiving gemcitabine.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>Messing E, Tangen C, Lerner S, et al.&nbsp; Plenary Session - Oral Presentation at the Annual American Urological Association Meeting on May 15, 2017.&nbsp; PNFLBA-10: Late-Breaking Abstract.&nbsp;</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>5b820a0adb18ab0054d8ff621f961987</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012643 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012643</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>A genome-wide association study yields five novel thyroid cancer risk loci</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012643">a4e2424adb18ab0054d8ff621f961913</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:31:32</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>5b820a0adb18ab0054d8ff621f961987</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">35e2424adb18ab0054d8ff621f9619da</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Thyroid</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>This new collaborative GWAS study included a total of 3,001 patients and 287,550 controls from five study groups of European descent, and the Ohio cohort of 1580 cases/1628 controls was used in the discovery phase. The results produced five novel risk loci (all with P values &amp;lt;3 &times; 10-8): 1q42.2 (rs12129938 in PCNXL2), 3q26.2 (rs6793295 a missense mutation in LRCC34 near TERC), 5q22.1 (rs73227498 between NREP and EPB41L4A), 10q24.33 (rs7902587 near OBFC1), and two independently risk associated variants at 15q22.33 (rs2289261 and rs56062135; both in SMAD3). The study also confirmed recently published association results from a Chinese study of a variant on 5p15.33 (rs2736100 near the TERT gene) and presented a stronger association result for a moderately correlated variant (rs10069690; OR=1.20, P=3.2 &times; 10-7) based on our study of individuals of European ancestry. In combination, these results create ample opportunities for future studies into the pathogenesis of thyroid cancer and clinical implications.&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Involved SPORE P50CA16058 investigators Drs. Albert de la Chapelle and Matthew Ringel.</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28195142</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Population Science</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>6687f18adb18ab00b86770c08c961902</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012596 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012596</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Ameliorating a signaling defect in melanocytes can reduce UV-induced melanoma in mice</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012596">3248bd8adb18ab00b86770c08c9619cf</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:45:16</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>6687f18adb18ab00b86770c08c961902</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">9458fd8adb18ab00b86770c08c961965</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Melanoma</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Individuals carrying variants of the melanocortin-1 receptor (MC1R) have red hair, fair skin and a higher risk for melanoma. In a study supported by the NCI (R01CA137098, R01CA193913 and R01CA196896), Dr. Ruitao Cui has shown that MC1R requires a lipid attachment through a process called palmitoylation to signal properly and make pigment to protect against exposure to ultraviolet (UV) radiation. In mice, MC1R variants are compromised for palmitoylation and are more sensitive to UV-induced melanoma. Administering these mice with palmostatin B, a small molecule that inhibits removal of palmitate from MC1R, greatly decreased melanoma formation. These studies indicate a potential intervention for reducing melanoma risk in persons carrying MC1R variants.</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28869973 and 28869972</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>c9e93182db18ab0054d8ff621f961946</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012600 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012600</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Building a program in extramural funding for Global Cancer Research: Bi-lateral funding programs in China, Russia, South Africa, Brazil, and Turkey</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012600">885ab182db18ab0054d8ff621f961916</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:54:05</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>c9e93182db18ab0054d8ff621f961946</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">365ab982db18ab0054d8ff621f961999</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Bi-lateral funding programs in China, Russia, South Africa, Brazil, and Turkey: CGH has participated in trans-NIH bilateral funding programs with China, Russia (CGH participated in the NCI U.S.-Russia bilateral program only), South Africa, Brazil, and Turkey since 2011. In FY2017, 5 R01 grants were funded under the U.S.-China Bilateral program, 10 R21s were funded under the U.S.-Russia Bilateral program, and one as a part of the U.S.-Turkey PAR.&nbsp; The ultimate purpose of these bilateral programs is to stimulate collaborative basic, translational, and clinical research between U.S.-based researchers and researchers in China, Russia, South Africa, Brazil, and Turkey.&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CGH</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<div>For CGH, Paul Pearlman took the lead</div>
<div>-U.S.-China: NIAID, NCI, NIMH, NINDS, OAR. NIAID was the lead.&nbsp;</div>
<div>-U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer (R21): NCI</div>
<div>-U.S.-Turkey: NIBIB and NCI. NCI was the lead.</div>
<div>-U.S.-South Africa: NIAID, NCI, NICHD, NIMH, FIC. NIAID was the overall lead, OHAM was the lead for NCI.</div>
<div>-U.S.-Brazil: NIAID, NCI, OAR. NIAID was the lead.&nbsp;</div>
<div>-U.S.-FAPESP (Sao Paolo research funding agency): FIC, NCI, NEI, NHGRI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDDK, NIDA, NIEHS, NIMH, NINDS, NINR, NIMHD, NLM, NCCIH. FIC is the lead, and no NCI grants have been awarded yet.</div>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>International Bilateral Funding Programs description on CGH Website: <a href="https://www.cancer.gov/about-nci/organization/cgh/research/international-bilateral-programs">https://www.cancer.gov/about-nci/organization/cgh/research/international-bilateral-programs</a> CGH Blog Post on the U.S.-Russia Bilateral Funding Program: <a href="https://www.cancer.gov/about-nci/organization/cgh/blog/2017/bilateral-partnerships">https://www.cancer.gov/about-nci/organization/cgh/blog/2017/bilateral-partnerships</a></div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>461bb10edb18ab00b86770c08c9619c1</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012604 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012604</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Brain tissue stiffness associated with tenascin expression regulates the aggressiveness of glioblastoma by bypassing protective activity of IDH1 mutational status</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012604">9a5bb54edb18ab00b86770c08c9619f0</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:58:37</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>461bb10edb18ab00b86770c08c9619c1</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">206bf54edb18ab00b86770c08c96199e</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Brain</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Glioma patients harboring mutations in the metabolic regulator isocitrate dehydrogenase 1 (IDH1) have increased overall survival time. Gliomas develop in a microenvironment that has compromised vascular integrity inducing hypoxia and HIF1a expression; however, the relationship between IDH1 mutations and HIF1a is unclear. Investigators in the Physical Sciences-Oncology Network (PS-ON) demonstrated a link between HIF1a-dependent hypoxia sensing, tenascin expression and an aggressive brain tumor phenotype. They showed that tenascin contributed to increased stiffness of the extracellular matrix, which causes repressed miR-203 expression to activate HIF1a-dependent tenascin deposition via a positive feedback loop. This study highlights the cellular plasticity and sensitivity of IDH1 mutant glioblastoma cells to matrix stiffness and oxygen tension.</div>
<div>&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 27820599; Article in Nat Cell Biol: <a href="https://www.nature.com/articles/ncb3429;">https://www.nature.com/articles/ncb3429;</a> Science Signaling Editor's Choice: <a href="http://stke.sciencemag.org/content/9/459/ec304;">http://stke.sciencemag.org/content/9/459/ec304;</a> PS-ON program website: <a href="https://physics.cancer.gov;">https://physics.cancer.gov;</a> Initiative: Physical Sciences-Oncology Centers (PS-OCs; U54) PAR-14-169; Physical Sciences-Oncology Projects (PS-OPs; U01) PAR-15-021</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>08483d0edbd4ab0054d8ff621f961933</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012598 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012598</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Building a program in extramural funding for Global Cancer Research: Promoting Clinical Studies on Pediatric Burkitt Lymphoma in Low-and Middle-Income Countries</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012598">df193d8edbd4ab0054d8ff621f9619cc</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:48:51</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>08483d0edbd4ab0054d8ff621f961933</sys_id>
<sys_mod_count>5</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">a4a9b182db18ab0054d8ff621f9619d0</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Lymphoma</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Supplements to Promote Clinical Studies on Pediatric Burkitt Lymphoma in Low-and Middle-Income Countries (2016); PAR16-086: In 2016, CGH announced a funding opportunity to promote clinical research studies on pediatric Burkitt Lymphoma (BL) in low-and middle-income countries (LMICs). These administrative supplements to NCI-designated Cancer Center grants aimed at facilitating research partnerships between NCI-designated Cancer Centers and partner institutions in LMICs to improve diagnosis and treatment strategies for pediatric BL burden in LMICs. The pilot research projects funded by these administrative supplements would support the clinical research needs for treatment of BL in the region. Six administrative supplements were awarded for FY16 and FY17.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CGH</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<div>CGH, Vidya Vedham took the lead &amp; OCC, Hasnaa Shafik and Henry Ciolino</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>Program Announcement PAR16-086 for Supplements to Promote Clinical Studies on Pediatric Burkitt Lymphoma: <a href="https://grants.nih.gov/grants/guide/pa-files/PA-16-086.html">https://grants.nih.gov/grants/guide/pa-files/PA-16-086.html</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>9c3cf1c2db18ab0054d8ff621f96197e</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012609 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012609</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Building a program in extramural funding for Global Cancer Research: R13 Conference Grants - NIH Support for Conferences and Scientific Meetings</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012609">34ac7dc2db18ab0054d8ff621f961916</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:04:15</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>9c3cf1c2db18ab0054d8ff621f96197e</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">25acb106db18ab0054d8ff621f9619a4</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>R13 Conference Grants - NIH Support for Conferences and Scientific Meetings (Parent R13) PA 13-347: In 2016, the NCI's Center for Global Health (CGH), through NOT-CA-16-070, clarified that various cancer-related topics for conferences and scientific meetings that are appropriate for PA-16-294 include topics that are relevant to the scientific mission of the center, which is to help reduce the global burden of cancer.&nbsp; In FY2017, the center awarded two R13 grants i) the Africa Cancer Leaders Institute, held within the larger biennial AORTIC conference, to foster innovative cancer research leadership in Africa via research training, networking and mentoring and ii) the 2017 APRU Global Health Program Annual Conference to address environmental exposures and cancer in the Pacific Rim. In addition, the center in collaboration with DCCPS, CHCRD and NIMHD has co-funded two R13 grants that address cancer and health disparities in the US and abroad.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CGH</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Fogarty, CGH, James Alaro</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>Program Announcement PAR13-347 for NIH Support for Conferences and Scientific Meetings (Parent R13): <a href="https://grants.nih.gov/grants/guide/pa-files/PA-13-347.html">https://grants.nih.gov/grants/guide/pa-files/PA-13-347.html</a></div>
<div>Notice: <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-16-070.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-16-070.html</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>639bf1c2db18ab0054d8ff621f961921</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012607 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012607</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Building a program in extramural funding for Global Cancer Research: Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care in Low- and Middle-Income Countries (R21)</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012607">032c35c2db18ab0054d8ff621f961981</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 19:02:12</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>639bf1c2db18ab0054d8ff621f961921</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">3b2cbdc2db18ab0054d8ff621f96190b</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care in Low- and Middle-Income Countries (R21) - PAR 17-474 NCI Notice NOT-CA-17-095: Stigma in HIV-infected people is a manifestation of self or societal disapproval and creates a barrier to getting tested, treated, and retained in care, especially in low and middle income countries (LMICs). In 2017, CGH on behalf of NCI joined a trans-NIH research Funding Opportunity Announcement (FOA) developed by the Fogarty International Center (FIC) to promote exploratory/developmental research applications that propose to address stigmatization of cancer of people living with HIV/AIDS (PLWH) in LMICs. The purpose of this FOA is to support pilot, stigma-reduction interventions in the cancer care continuum focused on improving biological and mental outcomes for PLWH and/or their caregivers specifically suited for LMICs. The R21 mechanism will be used to support these exploratory grants and each grant will receive two years of support.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CGH</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Fogarty, for CGH, Vidya Vedham took the lead</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>Program Announcement PAR17-474 for Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle-Income Countries (R21): <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-17-474.html">https://grants.nih.gov/grants/guide/pa-files/PAR-17-474.html</a></p>
<p>CGH blog: <a href="https://www.cancer.gov/about-nci/organization/cgh/blog/2017/stigma">https://www.cancer.gov/about-nci/organization/cgh/blog/2017/stigma</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>350a821adb14eb00b86770c08c961981</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012689 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012689</number>
<published>2018-09-04</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Adult Infiltrating Gliomas with WHO 2016 Integrated Diagnosis: Additional Prognostic Roles of ATRX and TERT</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012689">d79ace1adb14eb00b86770c08c9619a1</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-04 14:43:48</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>350a821adb14eb00b86770c08c961981</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">34aa025adb14eb00b86770c08c961906</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type>Brain, Central nervous system</x_26385_crs_kd_u_kb_cancer_site_type>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Collaborators from UCSF and Mayo Brain SPORE programs demonstrated that three genetic alterations (TERT promoter mutation, 1p/19q deletion, and IDH1 status) could discriminate sub-divisions of lower-grade glioma into distinct prognostic groups. The original work was published in 2015 in The New England Journal of Medicine (PMCID: PMC4489704) and contributed significantly to the decision of The World Health Organization to include these three molecular features in categorization of tumors of the central nervous system.&nbsp; More recently additional prognostic markers have been added, TERT mutation and ATRX alteration. Using data from 1206 patients from the UCSF Adult Glioma Study, the Mayo Clinic and The Cancer Genome Atlas (TCGA) they showed survival for each group and whether or not additional information on tumor TERT mutation or ATRX alteration was significantly associated with survival and could provide additional prognostic information. Overall survival was found to associate with patient age at diagnosis, grade, and ATRX alteration status and/or TERT promoter mutation status.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCTD</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMCID: PMC4489704</div>
<div>PMCID: PMC5432658&nbsp;</div>
<div><a href="http://cancer.ucsf.edu/research/spores/brain-spore/research-projects#one">http://cancer.ucsf.edu/research/spores/brain-spore/research-projects#one</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Post-Clinical</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>219af50edb18ab00b86770c08c96195b</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012603 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012603</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>A conserved NAD+ binding pocket that regulates protein-protein interactions during aging</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012603">38fa714edb18ab00b86770c08c96197f</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:56:52</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>219af50edb18ab00b86770c08c96195b</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">6afab14edb18ab00b86770c08c96197f</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>DNA repair is essential for life, yet its efficiency declines with age for reasons that are unclear. Numerous proteins possess Nudix homology domains (NHDs) that have no known function. This study showed that NHDs are NAD+ (oxidized form of nicotinamide adenine dinucleotide) binding domains that regulate protein-protein interactions. The binding of NAD+ to the NHD domain of DBC1 (deleted in breast cancer 1) prevents it from inhibiting PARP1 (poly adenosine diphosphate&ndash;ribose polymerase), a critical DNA repair protein. As mice age and NAD+ concentrations decline, DBC1 is increasingly bound to PARP1, causing DNA damage to accumulate, a process rapidly reversed by restoring the abundance of NAD+. Thus, NAD+ directly regulates protein-protein interactions, the modulation of which may protect against cancer, radiation, and aging.</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>DCB</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization/>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>PMID: 28336669</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>944bf1c2db18ab0054d8ff621f961990</article_id>
<article_type>text</article_type>
<author display_value="Jim Zhou">7acff4a96f6f2100e04fd15eae3ee451</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012605 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012605</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Building a program in extramural funding for Global Cancer Research: Mhealth: Technologies and Outcomes in Low-and Middle-Income Countries</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012605">399b35c2db18ab0054d8ff621f96190e</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>zhoujim@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:59:40</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>944bf1c2db18ab0054d8ff621f961990</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">3a9b39c2db18ab0054d8ff621f96196b</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<div>Mhealth: Technologies and Outcomes in Low-and Middle-Income Countries (PAR14-028): In low and middle-income countries (LMICs), where access to traditional health care is limited, there is a need for the development of mobile technologies in basic and applied biomedical research. In 2016, CGH on behalf of NCI lead the effort to join a trans-NIH research Funding Opportunity Announcement (FOA) developed by the Fogarty International Center (FIC) in promoting exploratory/developmental research applications that propose to develop and study innovative mobile health (mHealth) technologies. NCI plans to support projects that produce effective and sustainable mHealth interventions specifically targeted cancer research in LMICs. In FY17, NCI funded 1 R21 and plans to support eligible grants in FY18 and FY19.&nbsp;</div>
<div>&nbsp;</div>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CGH</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>Fogarty, for CGH, Vidya Vedham took the lead</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<p>&nbsp;Program Announcement PAR14-028 for MHealth: Technology and Outcomes in Low and Middle Income Countries (R21): <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-14-028.html">https://grants.nih.gov/grants/guide/pa-files/PAR-14-028.html</a></p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Other</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>4ed2b986db18ab00b86770c08c96199d</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012585 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012585</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Discovery of Epigenetic Intratumor Heterogenei</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012585">ed7375c6db18ab00b86770c08c9619ec</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:24:09</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>4ed2b986db18ab00b86770c08c96199d</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">329339c6db18ab00b86770c08c961937</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Tumors are highly heterogeneous and contain a mixture of morphologically and functionally distinct cell types. Of particular interest in a tumor is the cell population that drives tumor growth, at times referred to as cancer stem cells. The molecular basis for intratumor heterogeneity is only poorly understood. Tom Misteli and colleagues have identified an essential DNA-packing protein called linker histone H1.0 is present in varying levels in the cells of tumors, and plays an important role in determining which cells have the capacity to sustain the tumor&rsquo;s growth.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR, Francis Crick Institute in London, Hebrew University of Jerusalem</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 27708074</div>
<div><a href="https://ccr.cancer.gov/news/article/genome-organization-factor-determines-the-few-cells-that-make-a-tumor-grow">https://ccr.cancer.gov/news/article/genome-organization-factor-determines-the-few-cells-that-make-a-tumor-grow</a></div>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
<u_kb_template_top_accomplishment action="INSERT_OR_UPDATE">
<active>true</active>
<article_id>1a343986db18ab00b86770c08c961965</article_id>
<article_type>text</article_type>
<author display_value="Wei Yu">183afe6cdb26fe00593e76721f9619a0</author>
<base_version display_value=""/>
<can_read_user_criteria/>
<cannot_read_user_criteria/>
<category/>
<cmdb_ci display_value=""/>
<description/>
<direct>false</direct>
<disable_commenting>false</disable_commenting>
<disable_suggesting>false</disable_suggesting>
<display_attachments>false</display_attachments>
<display_number>NCI-KB0012587 v1.0</display_number>
<flagged>false</flagged>
<image/>
<kb_category display_value="Top Accomplishments">bef4810edb54ab0054d8ff621f9619e8</kb_category>
<kb_knowledge_base display_value="Basic Knowledge Base">f5644dcadb54ab0054d8ff621f9619d7</kb_knowledge_base>
<latest>true</latest>
<latest_aqi display_value=""/>
<meta/>
<number>NCI-KB0012587</number>
<published>2018-09-03</published>
<rating/>
<retired/>
<revised_by display_value=""/>
<roles/>
<short_description>Genome Organization Drives Chromosome Fragilit</short_description>
<source display_value=""/>
<summary display_value="NCI-KB0012587">1c74710adb18ab00b86770c08c96197b</summary>
<sys_class_name>u_kb_template_top_accomplishment</sys_class_name>
<sys_created_by>yuw5@nih.gov</sys_created_by>
<sys_created_on>2018-09-03 18:28:26</sys_created_on>
<sys_domain>global</sys_domain>
<sys_id>1a343986db18ab00b86770c08c961965</sys_id>
<sys_mod_count>4</sys_mod_count>
<sys_updated_by>yuw5@nih.gov</sys_updated_by>
<sys_updated_on>2018-09-13 18:52:23</sys_updated_on>
<sys_view_count>0</sys_view_count>
<text/>
<topic/>
<u_authorizing_group display_value=""/>
<u_review_needed>false</u_review_needed>
<u_url/>
<u_watch_list/>
<use_count>0</use_count>
<valid_to>2020-01-01</valid_to>
<version display_value="1.0">b174710adb18ab00b86770c08c9619ef</version>
<wiki/>
<workflow_state>published</workflow_state>
<x_26385_crs_kd_u_kb_cancer_site_type/>
<x_26385_crs_kd_u_kb_description><![CDATA[<p>Packing an entire genome inside the cramped quarters of a cell nucleus can put chromosomes at risk for damage, according to new research led by CCR's Andr&eacute; Nussenzweig. The findings suggest that DNA breaks are routinely introduced and then repaired as a cell folds and organizes its genome, and that when repair processes fail, these breaks can give rise to chromosomal abnormalities characteristic of cancer cells.</p>]]></x_26385_crs_kd_u_kb_description>
<x_26385_crs_kd_u_kb_doc>CCR</x_26385_crs_kd_u_kb_doc>
<x_26385_crs_kd_u_kb_fiscal_year>2017</x_26385_crs_kd_u_kb_fiscal_year>
<x_26385_crs_kd_u_kb_involved_organization><![CDATA[<p>NCI-CCR</p>]]></x_26385_crs_kd_u_kb_involved_organization>
<x_26385_crs_kd_u_kb_references><![CDATA[<div>PMID: 28735753</div>
<div><a href="https://ccr.cancer.gov/news/article/keeping-genome-organized-creates-opportunities-for-damage">https://ccr.cancer.gov/news/article/keeping-genome-organized-creates-opportunities-for-damage</a></div>
<p>&nbsp;</p>]]></x_26385_crs_kd_u_kb_references>
<x_26385_crs_kd_u_kb_research_type>Basic</x_26385_crs_kd_u_kb_research_type>
</u_kb_template_top_accomplishment>
</unload>
